Podcasts about pdms

Don’t get left behind on AWS! Don’t get left behind on AWS! Subscribe to our Newsletter: https://theultimatepartner.com/ebook-subscribe/ Check Out UPX: https://theultimatepartner.com/experience/ In this episode, we go deep inside the AWS Marketplace with Louise Strandoo, who spent nearly a decade building AWS’s marketplace business from the ground up and now leads partner development for AWS’s data, analytics, and storage practice. Louise unpacks COST, the six-pillar framework her team built by studying what actually separates hypergrowth startups and billion-dollar sellers from partners who treat marketplace as a side project. We break down why operational excellence has to be in place before you ever enable your sales team, why executive sponsorship from the top of the organization is what keeps a marketplace strategy from collapsing into a single point of failure, and why product-led growth is no longer optional now that buyers, and increasingly AI agents, expect to try, buy, and deploy software without waiting on a human to close the loop, https://www.youtube.com/watch?v=pwyAP7yVy3I Key Takeaways Success on AWS Marketplace requires a comprehensive framework like COST, not just a simple checklist of tasks. Your product must be something customers actually want to buy, not a subpar offering used merely to test the waters. Operational excellence is required to ensure your marketplace motion has the sustainability to scale globally. Product-Led Growth (PLG) is essential for enabling frictionless procurement, especially as buyers shift toward agent-driven AI solutions. Executive sponsorship is critical; building a strategy without leadership buy-in will prevent it from gaining real traction. Sales alignment ensures reps are appropriately compensated and friction is removed, preventing them from avoiding marketplace transactions. If you're ready to lead through change, elevate your business, and achieve extraordinary outcomes through the power of partnership—this is your community. At Ultimate Partner® we want leaders like you to join us in the Ultimate Partner Experience – where transformation begins. Key Tags AWS Marketplace framework, COST methodology, product-led growth, agentic procurement, hyperscaler ecosystem, operational excellence, revenue friction, private offers, co-sell acceleration, strategic collaboration agreements, resilient architecture, cloud commitments, organizational transformation Key Tags Louise Strandoo Audio Episode [00:00:00] Louise Strandoo: Salespeople, rightly so. They don’t wanna introduce something that’s going to add a complexity to the deal. They’re like, why would AWS wanna be involved? [00:00:11] Vince Menzione: You can feel it happening. The ecosystem is shifting beneath us, the way Hyperscalers are partnering, how AI’s remaking the channel and what it means to win in 2026. [00:00:22] Louise Strandoo: Welcome to the Ultimate Partner Podcast. I’m Vince Menzi. Own [00:00:26] Vince Menzione: your host. And each week I sit down with leaders at the intersection of technology, partnerships and outcomes. The voices shaping how ecosystems actually work. We talk about what’s real, what’s changing, and what it takes to lead in this era where the partner channel isn’t just part of the strategy. [00:00:45] Vince Menzione: It is the strategy because being in the room changes everything. Let’s start. [00:00:53] Louise Strandoo: And Louise Strand, come on out. Come on up. Uh, our first, our first [00:00:59] Vince Menzione: Amazon executive at, at this session. Not our first ever, but our first at this session. [00:01:06] Louise Strandoo: Happy to be [00:01:07] Vince Menzione: thrilled to have you. I, why don’t we sit down on an, um, I’ll have you sit here and, you know, you get, take one of the ultimate partner pillows with you since you’re a first assignment attend. [00:01:15] Louise Strandoo: Wonderful. [00:01:16] Vince Menzione: Uh, [00:01:16] Louise Strandoo: good [00:01:17] Vince Menzione: to hear. So great to have you. I thought maybe we’d start, maybe, uh, with you, uh, explaining your role. Then we can start talking about costs, which is the subject is like near and dear, and we’ll talk about that, about what that is. But I want to keep people on their pins of their seats right now. [00:01:33] Vince Menzione: So tell us, tell us more about you and your role and your journey at AWS. [00:01:37] Louise Strandoo: Yeah, well thanks for having me. Good to see everybody in the room. Um, so my name’s Louise. I have spent the better part of the last nine and a half years at AWS and I spent almost that whole time, probably around eight years. In AWS Marketplaces business Development organization, um, I joined to help startups figure out how to scale their business on the marketplace. [00:02:00] Louise Strandoo: And from there, I grew into a number of different roles, helped ISVs figure out how to scale their marketplace business of all sizes. Um, I worked with some of our top sellers on the marketplace, figure out how to really scale their revenue through the marketplace. Today I am actually the lead of the data analytics and storage partner development team. [00:02:20] Louise Strandoo: Nice. Within the US Tech partnerships organization. So it’s been a really cool transition to go from like all marketplace focused. And throughout that time, marketplace kind of became the center of partnerships. Yep. Within our partner program. Um, so now I manage PDMs and partners and we still talk a lot about marketplace. [00:02:40] Louise Strandoo: Also everything else that we do as a partner. So it’s, um, it’s been a fun journey. [00:02:45] Vince Menzione: And we were talking about this earlier, like you started with Marketplace and then moved out where all the other organizations started from partnership and moved into marketplace. Mm-hmm. Almost the other up. And you have built a framework costs [00:02:59] Louise Strandoo: mm-hmm. [00:03:00] Vince Menzione: Characteristics of successful sellers. And I have a set of operating principles about successful partnering. So I’m really intrigued about this conversation. I was hoping you could walk us through it, like what are these characteristics and where do most partners fall short in terms of characteristics? [00:03:18] Louise Strandoo: Yeah, so, um, like all really good things, cost was an effort that I built alongside a bunch of other really smart people. And we started to have this conversation about what does, uh, you know, what does success look like? We we’re focused in the beginning, in my marketplace journey on getting. Partners to sell on the marketplace, getting them to list and adopt the features. [00:03:41] Louise Strandoo: And of course they’re like, why would we do this? And we’re like, that’s a great question. Let’s figure out like really what the why of this whole thing is. And as we started to get partners who were startups and some of our really large partners activated, we started to see all kinds of value and how marketplace was helping co-sell and all this good stuff. [00:03:59] Louise Strandoo: And we needed to figure out like how do we identify what is like the lightning in the bottle? So we looked across some of the most, uh, hypergrowth companies on the marketplace. Mm-hmm. Some of those startups that had really propelled into major success stories. And then some of those like really scaled enterprise sellers, the one [00:04:17] Vince Menzione: that got to a billion dollars. [00:04:18] Louise Strandoo: Exactly. The market, our billion dollar market market. Billion dollar sellers. Right? Yep. And we looked at what are the common characteristics that all of those partners embody. Yes. And how do we kind of. Define a framework that is not a checklist because a lot of us were doing that at the time. Here’s all the things that you should do to make it work well. [00:04:34] Louise Strandoo: It doesn’t really work from partner to partner. Everyone has a unique go-to market strategy. Yeah, so we developed costs to kind of be this overarching tool that partners can use to say, do we have the right kind of fundamental approach to how we’re going to market with AWS and how we’re thinking about the marketplace. [00:04:51] Louise Strandoo: Do we have the right tools to like bring our overall go-to-market strategy to A AWS and to the marketplace so we’re not doing two separate things. That was sort of the genesis of the idea. Makes [00:05:02] Vince Menzione: a lot of sense. [00:05:04] Louise Strandoo: So, um, the characteristics, there’s six of ’em. I won’t go into detail about every single one. [00:05:11] Louise Strandoo: Oh, [00:05:11] come [00:05:11] Vince Menzione: on. We’ll do that one. Yeah. We have some people in the room that are gonna be intrigued by this. Go ahead. [00:05:16] Louise Strandoo: So, um, the first pillar is. Partnership with AWS, you can’t do marketplace without figuring out what, what’s your overall partner strategy, right? So how are you using the partner programs to drive differentiation in your business? [00:05:30] Louise Strandoo: Yep. How are you using our funding programs to elevate the parts of your business that you really wanna accelerate? Um, and how are you thinking about your partner strategy with AWS overall? [00:05:40] Vince Menzione: Interesting. [00:05:41] Louise Strandoo: The second one is, uh, selection on AWS marketplace. [00:05:44] Vince Menzione: Product selection. [00:05:45] Louise Strandoo: That’s right. [00:05:45] Vince Menzione: Yeah. [00:05:46] Louise Strandoo: You gotta have a product on the marketplace that your customers wanna buy. [00:05:49] Louise Strandoo: I think the biggest thing that partners have done wrong over the years is they think, let’s do crawl, walk, run. We’re gonna put something up there that we’re not, you know, really excited about, but we’ll see how it does and then we’ll try to invest from there. [00:06:03] Vince Menzione: Mm-hmm. [00:06:04] Louise Strandoo: If you put something out there that nobody knows how to sell, then that you’re not excited about, your customers aren’t probably excited about it either. [00:06:09] Louise Strandoo: There’s no reason it’s gonna do well in the marketplace. [00:06:10] Vince Menzione: Yeah. It makes no sense to me. [00:06:12] Louise Strandoo: Yep. So you gotta have something good. You gotta have your marquee product, and then you wanna use features that are gonna help buyers actually access that product in a way that’s frictionless. Yeah. The third one is operational excellence. [00:06:25] Louise Strandoo: So that’s looking at how are you structuring your organization and investing in all the right processes that you need to scale the business. Reporting at a global scale, understanding how to recognize revenue and thinking about all of the in-between moments of. Being on the marketplace, creating an offer, how does your sales team gonna get in touch with you when you need to send that offer out? [00:06:47] Louise Strandoo: And how are you making sure that an alliance person isn’t trying to find an outlet in a random corner of an airport to send a private offer to a customer? All of that structural stuff to make the, the motion scale. [00:07:00] Vince Menzione: So we’re talking product led growth versus. One off or [00:07:04] Louise Strandoo: all of it? All of it. Okay. No matter what kind of partner you are, you have to have operational excellence. [00:07:08] Louise Strandoo: Yeah. To make sure that your marketplace and your partnership motion has sustainability and scale. The next two, I’ll kind of go through fast. There is, yeah. Um, partner commitment to marketplace revenue. So what do you really want Drive from a revenue perspective, right. How do you get your leaders bought in on that, and how do you set a goal that dictates what you’re doing? [00:07:28] Louise Strandoo: And then how do you define sales alignment? From a structural perspective to say we’re gonna remove friction that could get in the way of the field selling this thing. We’re gonna remove things that are, um, negating reps from wanting to go through marketplace because it’s impacting their comp. Yeah. Or it’s really hard. [00:07:46] Louise Strandoo: All of that kind of structural stuff goes into the sales alliance. [00:07:49] Vince Menzione: So there’s, yeah. I wanted to take this apart a little bit too, if you don’t mind. No [00:07:52] Louise Strandoo: problem. [00:07:53] Vince Menzione: Because I think about this a lot. So when you start talking about an organization, you’re talking about what this, we’ll call it an ISV Sure. Or an si, but. [00:08:00] Vince Menzione: You know, ISPs primarily is where it all started. They need to get their internal operational excellence. Right, exactly. Which means their, their ops piece. Yep. And their sales execution. They’re gonna to market all those things. The sales alignment side. Is that their sales teams [00:08:18] Louise Strandoo: correct. [00:08:19] Vince Menzione: Are compensated properly so that they don’t go around the systems. [00:08:22] Vince Menzione: Exactly right. They’re aligned. They’re aligned to go drive the right results. [00:08:25] Louise Strandoo: Exactly. [00:08:26] Vince Menzione: Because they’ve made commitments as well. [00:08:28] Louise Strandoo: Yeah. [00:08:28] Vince Menzione: Yeah. [00:08:29] Louise Strandoo: And I always talk about marketplace, like it is transformation. It’s different. It’s not what you’re doing today. [00:08:35] Vince Menzione: That’s right. [00:08:35] Louise Strandoo: Salespeople, rightly so. They don’t wanna introduce something that’s gonna add a complexity to the deal. [00:08:43] Louise Strandoo: They’re like, why would AWS wanna be involved? Stay away. So if that is already there and then on top of that Mm, they don’t get paid as much when they go direct. [00:08:53] Vince Menzione: Right? Right. [00:08:54] Louise Strandoo: They’re not gonna go through the market nice. [00:08:55] Vince Menzione: No, they’re not. [00:08:55] Louise Strandoo: They’re not gonna bring anything to you and the partnership team saying like, Hey, we really wanna figure out how to make this engine work with AWS So we have to do as much as we can to remove that friction from the experience. [00:09:06] Vince Menzione: So, you know, you mentioned private offers, which made me think about like product-led growth versus private offers. ’cause it’s, it feels like marketplace from the beginning. It’s changed. It [00:09:15] Louise Strandoo: has, [00:09:16] Vince Menzione: you’ve been doing this for a number of years. You were first to market with a marketplace. There was, I’ll call a lot of friction because there was channels and other, other routes to market direct selling. [00:09:27] Vince Menzione: Tell us, take us through some of those experiences. Yeah, yeah. Like what was that like? And then obviously you built cos because you had a lot of field engagement with these organizations trying to get them to go do it the right way. [00:09:38] Louise Strandoo: Right? [00:09:39] Vince Menzione: Yeah. [00:09:39] Louise Strandoo: So it’s interesting actually, when we built the marketplace. [00:09:42] Louise Strandoo: It was completely like a product-led growth motion, as in let’s just figure out a way to let AWS customers find amis in the marketplace. Developers are gonna go get it, and they’re just gonna buy it without any additional push from the field or like co-sell. That doesn’t need to happen. Then we heard from customers, Hey, this is great. [00:10:02] Louise Strandoo: But what we really want is also to be able to buy bigger contracts. We wanna customize our contracts, we wanna negotiate price when we’re buying this on behalf of, you know, large organizations. We’re not just buying what’s on the shelf. We need something more custom. So we introduced this concept of private offers to make sure that we could bring all of that customization into the process. [00:10:23] Louise Strandoo: And then we heard from customers saying, uh, we want to purchase from our preferred channel partners. We really wanna make sure that we’re, you know, not losing that source of, um, engagement with our really critical partners. So we had to figure out, hey, how can we make it so that we’re not competing with the channel? [00:10:41] Louise Strandoo: ’cause we’re not really a channel at all. Right. So we had to go and build our platform that allowed for channel partners to sell through the marketplace and augment that private offer piece to say, Hey, if you want, you can have a channel partner resell your product through the marketplace. So today we kind of see all of those as just different routes to market and different ISVs are gonna embrace different routes to market. [00:11:04] Louise Strandoo: First, the really important thing about costs is that it’s. Pushing partners to think about bringing their go to market strategy that works outside of the partnership to the marketplace. Mm-hmm. So if you’re an ISV that doesn’t sell with channel today, don’t start with channel partners on the marketplace. [00:11:21] Louise Strandoo: Right. If you don’t do product-led growth today, probably figure that out before you start doing it on the marketplace. Yeah. But if you’re doing those things, if you’re not doing those things, you should look at why not, and could we be doing those things and then we have the ways to bring it into your strategy with AWS marketplace. [00:11:38] Vince Menzione: So what separates the partners who kind of build this flywheel of success that you describe from those who treat it maybe as a side project? And do you, do you see less and less of that today too? I wanna, I wanna ask you. [00:11:50] Louise Strandoo: No, I think, um, the more mature the marketplace gets [00:11:57] Vince Menzione: Yeah. [00:11:58] Louise Strandoo: The more obvious some of the, uh, characteristics of success become and the more important. [00:12:06] Louise Strandoo: Embodying that framework becomes for partners as they grow to become the next billion dollar seller, right? And become the next a hundred million dollar seller. Um, I think a couple things come to mind for me. The first thing is that like at AWS overall, we talk a lot about like resilient architecture. We talk a lot about what does it look like to drive successful transformation. [00:12:29] Louise Strandoo: All of that has to happen in the partnership. Partners that have really strong marketplace motions with AWS, they do not have single points of failure. They are not expecting an alliance lead to manage everything and then have the business collapse if they leave. [00:12:46] Vince Menzione: Yeah. [00:12:46] Louise Strandoo: They figure out how to delegate and get buy-in from leadership so that they have multiple folks invested in the strategy for multiple angles so that there’s scalability and sustainability. [00:12:58] Louise Strandoo: Without that. You could do all the things right with costs and if there’s res, if there’s no resiliency, if there’s, if there’s a single point of failure, it doesn’t scale and it doesn’t last. [00:13:09] Vince Menzione: It’s so funny ’cause you haven’t seen my seven principles of, of successful partnering, but we talk about growth mindset, we talk about executive commitment and then clarity on your vision and what you’re hoping to achieve. [00:13:21] Louise Strandoo: Yeah. [00:13:22] Vince Menzione: Like that’s your internal victory. You’ve gotta get those things right. That’s exactly what you just said. A hundred [00:13:26] percent. [00:13:26] Louise Strandoo: And you can’t, you, you know, like if you don’t have that executive sponsorship, [00:13:30] Vince Menzione: yeah, [00:13:32] Louise Strandoo: great. You’ve done the cost framework, but where are you gonna go with it? [00:13:35] Vince Menzione: And it’s not just the sponsorship, it’s. [00:13:38] Vince Menzione: Up in, from the top of the organization all the way down to the selling floor. Completely. Right? [00:13:42] Louise Strandoo: Completely. [00:13:42] Vince Menzione: Everybody has to be aligned. Resources, investments all need to be aligned to this. Mm-hmm. [00:13:47] Louise Strandoo: Mm-hmm. [00:13:47] Vince Menzione: We’re speaking the same language earlier. A hundred percent. I love it. I love it. I love it. Um, so what does, we talked about product-led growth, but I want to maybe jump in here a little bit more. [00:13:58] Vince Menzione: Because I think it’s, it’s becoming more prevalent today, isn’t it? Yeah. It’s like, you know, we talked about private offer. It was really private offers, at least my perspective was a few years ago, I wanna buy something from you. Oh, you have a cloud commitment. I can access the cloud commitment. [00:14:13] Louise Strandoo: Yeah. [00:14:14] Vince Menzione: And so it was always the private offer thing that was going on behind the scenes, which required a lot of internal resources to go drive. [00:14:19] Louise Strandoo: Yep. [00:14:20] Vince Menzione: Let’s talk about product led growth. ’cause that becomes a fly more of a flywheel that’s automated Yeah. And allows you to sell while you’re sleeping kind of thing, you know? [00:14:28] Louise Strandoo: Totally. [00:14:29] Vince Menzione: Yeah. [00:14:30] Louise Strandoo: So I think, um, we have heard a lot from customers saying, okay, when we really need to negotiate and we need something custom, we wanna be able to do that. [00:14:40] Louise Strandoo: But we also wanna be able to purchase things quickly. We don’t wanna have to go out to dinner every time we need to upgrade, uh, like our licenses and get a new contract. We wanna be able to experiment and pick the things that resonate best with the line of business users that are, you know, increasingly taking some of that buying power. [00:14:59] Louise Strandoo: And I think especially now that we’re entering into, you know, the unprecedented, unprecedented times, it’s everything is AI like. There is more, um, pressure than ever to have users quickly figure out, does something add value to me and my business right now? And if it does, then I’m gonna keep using it, and if it doesn’t, I’m gonna go to the next thing. [00:15:22] Guest: Right. [00:15:22] Louise Strandoo: Product led growth is really about eliminating some of that I would say. Paperwork at the start of the process and putting the power in the hands of the user to say, can this product solve your challenge? And as more and more buyers are looking at Agen solutions, they wanna be able to try something, see if it works, and then quickly buy it without having to go through a whole bunch of steps because they have work that needs to be done right now. [00:15:54] Louise Strandoo: So the marketplace, that was our roots, like we started with this PLG motion. So we have all of that foundation to do it, and we’ve spent a lot of time over the last two, three years, like really investing in that from our engineering and roadmap perspective to build a whole bunch of features and capabilities that support product-led growth. [00:16:11] Louise Strandoo: We have things like free trials request, demo request, a private offer if you want to. Um, we introduced something, you know, last year that was an express private offer experience. Hey, you know, you want custom pricing. Request it and we’re gonna give it to you right away because the vendor has populated rate cards. [00:16:26] Louise Strandoo: Right? So all of those things I think are really important right now to say, yeah, when your customers like, wanna get going, now let’s stop. Putting barriers in the way and let your product actually show its value immediately. [00:16:38] Vince Menzione: And you were actually putting buttons or making buttons available Yeah. For people’s websites. [00:16:42] Vince Menzione: Exactly. So they could just say, click here and [00:16:43] Louise Strandoo: buy. Absolutely. We buy with a Ws. You can click from your own website, your own marketing pages to route them to the marketplace. If that’s the preferred way to transact, [00:16:50] Vince Menzione: yeah, why not? [00:16:51] Louise Strandoo: Yeah. [00:16:52] Vince Menzione: So you mentioned ai. We talked a little bit, I call it the tectonic shifts. [00:16:56] Vince Menzione: We, we’ve seen this incredible transformation happening so fast. And now we’re talking about agents. Right. And, uh, John Yo was over here from, uh, earlier from Sugar talking about like, what happens if the buyer is an agent? [00:17:08] Louise Strandoo: Totally. [00:17:09] Vince Menzione: Let’s talk about that. [00:17:10] Louise Strandoo: Yeah. I mean, I think that PLG and like is the right thing to enable a agentic procurement. [00:17:18] Vince Menzione: Yeah. [00:17:19] Louise Strandoo: If, um, you know, like in the, uh. 2019 when private offers were like, that was the big boom. We were like getting people to sign up on the marketplace. All we were focused on was private offers. So many sellers would have products on the marketplace where you’d click and purchase it and it would just say, thanks for buying, and it’d be like, we’ll get in touch with you and like a 24 hours and then we’ll figure it out. [00:17:42] Louise Strandoo: No worries. Thanks for buying. If that doesn’t work. If you’re an agent, it doesn’t work. An agent would be like, okay, this is like a dead end, right? Yeah. Agents are gonna look for products that they can purchase and begin using instantaneously. So yeah, product-led growth is like a really good, um, strategy that ISVs can use to future proof their business and make sure that they’re not just catering to an evolved. [00:18:06] Louise Strandoo: You know, procurement persona who maybe is looking for that faster transaction, but also preparing for that agent persona. Yeah. That is gonna be helping make software procurement scale. [00:18:17] Vince Menzione: So what do the partners in the room need to do to rethink how they think about this? [00:18:22] Louise Strandoo: I think there’s a couple things. I think you know, number one, you can look at the cost framework and start to use it as a jumping off point to evaluate your business. [00:18:31] Louise Strandoo: You can look through a bunch of resources that we’ve put out around costs, and one of the first blogs that I wrote has a Buzzfeed style quiz. You can go through and be like, where are we at? And if you realize after you run through that exercise that you’re farther away from where you wanna be in terms of partnering with AWS, it’s a really good dump like starting point to be like, great, here’s the challenges. [00:18:56] Louise Strandoo: But the biggest message I would relay to the partners is. Do not wait to try to go build this and then bring it to your executives and say, look what I built. It’s not gonna go anywhere. You need to go and use that as the cry to your leadership team. Like escalate. Now here’s the opportunity that we have with AWS. [00:19:17] Louise Strandoo: Let’s look at all of the awesome studies that we and our partners have put out over the years. Look at your competitors that are in the marketplace, your competitors that are partnering with AWS, and start there by saying, we’re. Behind or we’re missing in these areas. We could be doing, you know this, to make our product more a ag agentic ready. [00:19:37] Louise Strandoo: We could be doing more in marketplace to ensure that we’re capitalizing on the private offer business, and we need to figure out how we’re gonna drive commitment now so we can go and build this if you try to build it. Then show the value later. It’s gonna be really hard to then be pushing that boulder up the hill. [00:19:55] Louise Strandoo: So the more that you can lean into getting the sponsorship early on, you’re gonna have a much easier time then navigating, you know, all the hard work that comes with partnership co-sell, um, and, and everything kind of fun that we get to do once we get to go to market with our partners. [00:20:10] Vince Menzione: Do you have one piece of advice for each one of the. [00:20:13] Vince Menzione: Conditions or characteristics for, for, for this group to follow or [00:20:17] Louise Strandoo: think about? I think that, um, the, we didn’t talk about the last one, which is a good one to end on, which is enablement. [00:20:22] Vince Menzione: Yes. [00:20:23] Louise Strandoo: Enablement starts with like most of the time, ISVs in particular, and this, it goes for channel partners as well. [00:20:30] Louise Strandoo: They’re like, we gotta enable the field go and enable all the salespeople why they should do all this stuff. You have to do these things like in some sequence though. So if you go and enable the field, everybody do marketplace and they’re like, how? Where do we go, right? Do we send you the leads? Are we slacking you? [00:20:47] Louise Strandoo: Like are we emailing? Like what do we do? You have to then go back and be like, actually, our operational excellence isn’t sorted out. We need to do that first. And who needs to be enabled from that side of the house? Like don’t forget to enable your rev ops teams, your deal desk teams, all of the teams that are kind of essential to making your partnership with AWS Hum need to be enabled in the way that is relevant for their business. [00:21:10] Louise Strandoo: So when you, you know, think about like what do you need to do across all the pillars? It’s gonna be different depending on what your go-to-market focus is. If you’re a hundred percent focused on selling through SIS today and through channel, maybe product-led growth is not the top priority, but then you need to go and figure out, okay, so how have we. [00:21:28] Louise Strandoo: Figured out which partners we wanna work with on AWS and how have we enabled them and have we communicated that enablement to our salespeople? Are we removing unnecessary barriers to them transacting? That’s what you really gotta figure out. So it’s really about looking at how you execute outside of marketplace, outside AWS, figuring out what that, what are the strongest pieces that you do in your business today, across those pillars, and then asking to replicate that with your partnership with AWS. [00:21:56] Vince Menzione: Nice. So to the room here is, um, if someone in this room doesn’t, does one thing differently on the marketplace, what should it be? [00:22:08] Louise Strandoo: There’s so many things I can think about. I think like first [00:22:12] Vince Menzione: you’re coaching ’em [00:22:13] Louise Strandoo: individually, [00:22:13] Vince Menzione: by the way. Just think about it that way. [00:22:15] Louise Strandoo: One of the first things like, it depends on where you’re like, where you’re at in your journey. [00:22:18] Louise Strandoo: So like, quick show of hands, who is, um, a partner that is like using the marketplace today? [00:22:26] Vince Menzione: There’s quite a few actually. [00:22:27] Louise Strandoo: Okay. Awesome. Thank you for helping drive the marketplace. So for those of you that raised your hands, like my sentiment to you all would be figure out how you are incorporating marketplace as the center of your strategy with AWS. [00:22:44] Louise Strandoo: We are increasingly using marketplace as the point of scale for all things about partnership. All things funding are like increasingly requiring some hook into marketplace. So we can actually provide more funding and scale increase like more. So think about like how do you use marketplaces that like center of your partnership, um, for those of you that are not on the marketplace today and are thinking like, is this something that is valuable to me? [00:23:15] Louise Strandoo: Is this something that I should think about and do? You should absolutely. Go look at who are your competitors? Who are the folks that are already out there on the marketplace and, and why aren’t you there? And then you should start to look at what are the characteristics of successful sellers to map out What could we do and what’s the kind of order of operations that we should take to figure out like, how do we get there? [00:23:40] Louise Strandoo: How do we have a plan from the beginning to get buy-in for our partnership with AWS so that we’re not going about it, expecting that it’s gonna just like drive a bunch of leads to the business. It’s not what it does well, but it is gonna help accelerate the way that you co-sell with AWS, which can be a tremendous value add when done appropriately. [00:23:58] Louise Strandoo: So I think, yeah, like figure out the right way that it’s gonna unlock business value depending on what’s most important to your priority. Um. Today [00:24:08] Vince Menzione: we have about three and a half minutes, and I, I’m eager to see if there’s any questions. I, I, um, I, John’s right here with the mic and I love that. I love the, want to get the interaction here in the room. [00:24:19] Louise Strandoo: Yeah, [00:24:20] Vince Menzione: it’s a great group. [00:24:25] Guest: Oh, [00:24:29] Vince Menzione: can they light up that mic? Maybe [00:24:33] Louise Strandoo: Good. [00:24:37] Vince Menzione: There you go. That’s fine. There you go. It’s working. Alright. [00:24:41] Guest: Thank you so much. This is a really great presentation, first of all. I love it. Um, I’m actually part of the, uh, the GSI, so I work cognizant. My name is Ana Hill, um, and I’m manage alliances with ServiceNow. Um, our goal is in the really near future to really engage with all the hyperscalers in sell. [00:25:00] Guest: So that’s one thing. But my interesting, my question is how do you, how, how does AWS measure success? Of the partners who are on your platform, what are the metrics? How do you determine which partners are actually successful and what other partners can use to learn from that? [00:25:19] Louise Strandoo: Yeah, that’s such a great question. [00:25:21] Louise Strandoo: So, um, something that I think is like super helpful that you bring up is cost is not a, um, a scorecard that says everybody that does all these things is a good partner. It’s basically inputs that we have come up with that are supposed to help with the partnership outcomes. Um, so partners, we measure a whole bunch of different things. [00:25:47] Louise Strandoo: I think PDMs and my team carry goals across like seven different categories. There’s a couple of big things that we look at. We look at the revenue that you drive through the marketplace, so whether that’s through private offers or through your self-service business or through. Selling through a reseller, or if you are the reseller, like what is that resell business or driving? [00:26:05] Louise Strandoo: Um, we look at what are the opportunities that you’re bringing and sharing with AWS and that you’re launching. So through our lead sharing mechanism. Not only what are you launching, but what are you sharing with us that is qualified that you’re bringing the field into? Um, we look at things like migrations and migration, realized revenue. [00:26:25] Louise Strandoo: How are you helping drive customers to the cloud? And how are you helping customers not just get everything set up, but you start actually using it. Um, so we really are gonna look across like a multitude of those metrics and when we look at like which partners are kind of leading the way. We’re gonna start to look at the revenue in those buckets, right? [00:26:44] Louise Strandoo: Like who’s sharing and bringing and growing with us? Who’s bringing more opportunities to engage before it happens on the marketplace? Who’s actually completing that transaction? And then who are helping who, who are the partners? Kind of like leading those big types of transformations, migrations, and, and realize revenue. [00:27:00] Louise Strandoo: This is really great. Yeah. Yeah. [00:27:04] Vince Menzione: Thank you. Any other questions? Come on. We’ve got 30 seconds left. We have time for that one last question. Run over there. John. Come on. [00:27:17] Guest: Thank you again, a great, uh, presentation. One question I had is, uh, this morning, right Jay from, uh, oia, right? He identified a whole bunch of, uh, companies that are doing. [00:27:28] Guest: More than a billion dollars in revenue with AWS. [00:27:30] Louise Strandoo: Mm-hmm. [00:27:31] Guest: What would you say are one or two top qualities among these companies that help some drive? I can give [00:27:36] Louise Strandoo: six. And they’re all of these. Yes. [00:27:39] Vince Menzione: The cost, [00:27:40] Louise Strandoo: but like, I think, um, so I love it. Yeah. My, my team we’re working on some content to better capture, like Yeah. [00:27:48] Louise Strandoo: You, you’ve gotten there, you’ve done the six basic things. Now what happens when you’re a billion dollar business? What does it look like there? It’s a lot of the same stuff, right? Like billion dollar billers on the marketplace. They embody that resilience, for example, in their operational mechanisms. [00:28:03] Louise Strandoo: They’re moving beyond the point of there being like one person that creates private offers and they’re like just part of the partnership team. They activate their, um, their deal desk to really manage private offers and marketplace business at scale. They’re integrating their pipeline to share deals proactively through their CRM system and they have really targeted enablement that is. [00:28:24] Louise Strandoo: Really pushing to the field to make sure that every person in their team understands the value of cloud value of AWS and how marketplace accelerates the pipeline. So the more mature that you become as a marketplace seller, like the more that cost is relevant to help keep you on track and be that kind of north star to say like, you could do a cool bunch of stuff with us, but here’s really where you wanna check and see, like what can you do to evolve the business to the next stage? [00:28:49] Vince Menzione: What you’ve said is so like impactful and we have some experts in the room that do this. They help these organizations better understand it’s really getting into your field organization to help them understand how to. How to show up for meetings with AWS re, like how to, how to, uh, co-sell together, how to think about going after these opportunities. [00:29:09] Vince Menzione: What, when you’re, when you’re talking to customers, potential customers about their cloud commitments, like what are the right questions to ask in the pro? There’s so many things, like I’m sure the costs six has like 150 each [00:29:21] Louise Strandoo: Easily [00:29:21] Vince Menzione: steps. Yeah. You know, to it. [00:29:24] Louise Strandoo: Yeah. And I think like, just to follow on that. [00:29:26] Louise Strandoo: Um, we have partners who have gone and they’ve been like, okay, we’re getting a strategic collaboration agreement with AWS. We’re getting funding, and if they don’t have this, it doesn’t work. It doesn’t work. It fails. So this is really like, yeah, it’s about building that resilient architecture to say, if we go big, do we have the execution plan to succeed? [00:29:47] Louise Strandoo: You can’t start with a plan to say, give us a bunch of funding and we’ll go do it. Your salespeople will say. Know what that is. Don’t care. Yeah. So you have to put all of that, you know, all of those building blocks in first to make sure that we can actually execute. [00:30:01] Vince Menzione: You need alignment from the executive suite down to the selling floor. [00:30:05] Louise Strandoo: A hundred percent. [00:30:06] Vince Menzione: Yeah. [00:30:06] Louise Strandoo: Yep. [00:30:06] Vince Menzione: That’s really what it’s all about. [00:30:07] Louise Strandoo: Yep. [00:30:08] Vince Menzione: Louise, thank you so much. It’s been incredible. So great to have you join us. Thank you [00:30:15] so [00:30:15] Louise Strandoo: much. Yes, thank [00:30:16] Vince Menzione: you. [00:30:16] Louise Strandoo: Thank you, [00:30:16] Vince Menzione: thank you. Thanks for listening to The Ultimate Partner Podcast. If today’s conversation resonated. Share it with a partner leader in your network. [00:30:26] Vince Menzione: Subscribe where you listen, and head over to the Ultimate partner.com for show notes related content and the resources for this episode. And if you haven’t already, now’s the time to register for the Ultimate Partner Live event in Reston, Virginia, October 26th through October 28th. Until next time, keep showing up in the rooms that matter because being in the room changes everything.

In der neuen Folge erzählt Sarah vom Buzz & Beyond Summit in Wien, warum sie sich oft auf Branchen-Events fehl am Platz fühlt, Steff beschäftigt ein vermeintlich rassistischer Vorfall in Linz am Bahnhof und die bewusst Entscheidung ein Ally zu sein. Die beiden besprechen aber natürlich auch die aktuellen Schlagzeilen rund um Snowboarder Benjamin Karl, welche Reaktionen das in beiden ausgelöst hat und warum es wichtig ist über solche öffentlichen Statements zu sprechen. Es gibt Bezugnahmen in Form einer Sprachnachricht zum Thema PMS und PDMS und am Ende reden beide über die Frage, wie es sich eigentlich anfühlt so viel über die eigene Beziehung Preis zu geben.

In this episode, Wade breaks down one of the most confusing topics in long range shooting, ballistic drag models.What is BC?Why does it matter?And which one should you actually be using?We cover:What ballistic coefficient (BC) really meansWhy higher BC isn't always the full storyG1 vs G7 (and why G1 needs to go)When G7 is more than enough for huntingWhat CDMs and PDMs are, and when they actually matterThis is part of Wade's long range “library” series, built to give hunters practical, usable knowledge without getting lost in the weeds.If you've ever been confused about what to plug into your ballistic app… this is the one.

Say goodbye to messy curly cords and more potential failure points.Steering wheel-mounted controls make it easier to adjust key functions on the fly, but getting those signals from the wheel to the car is not as simple as it sounds. Running multiple wires through a rotating steering column is unreliable, time-consuming, and they can be prone to failure due to the nature of their use. Zestek has developed a CAN-based steering wheel PCB solution (CAN hub) that simplifies installation, reduces wiring complexity, and integrates seamlessly with MoTeC ECUs, dashes, and PDMs.Use ‘PODCAST75' for $75 off your first HPA course here: https://hpcdmy.co/hpa-tuned-inWith only four wires required for full functionality (CAN high, CAN low, power, and ground), this system eliminates the need for bulky wiring looms. The pogo pin system built into the quick-release hub provides a clean and hassle-free connection, removing the need for traditional curly cords. A pre-configured DBC file is available for MoTeC users (and we're sure more in the future), while others can configure the CAN signals using a spreadsheet for quick setup.Each button and switch is fully customizable, including momentary and latching functions, as well as full-spectrum RGB LED feedback. Paddles can be used for more than just shifting, allowing functions like anti-lag, launch control, and nitrous activation. It is also sim racing compatible, making it easy to use the same wheel for both real and virtual driving while you wait out the winter weather.

After 1.5 years into this process I'm going to give an update on my multiple PDMs (poly-domestic marriages) in several different countries, including what's going on and what I've learned and changed.

In this podcast episode, MRS Bulletin's Sophia Chen interviews Gwangmin Bae of Korea University about his work with colleagues on the design of a new smart window system that utilizes compression. Like other smart windows, this window makes use of pores within the material to adjust its transparency. However, instead of using a stretchy material that controls light scattering through the pores, Bae and colleagues used a material that compresses in thickness. That is, the window becomes more transparent when it is compressed. The researchers place this structured porous material made of the polymer polydimethylsiloxane or PDMS between two panes of glass to create the smart window. This work was published in a recent issue of Nature Communications.

Send us a Text Message.$100 off your HP Academy course purchase! Use Code: BLIND100Its a big decision to pick and dash and/or pdm... and I sit down with Andre Simon to discuss what to take into account and some best practices to set them up! Both can be just seen as IG bling OR super powerful tools to help improve your racing and your race car! Support any of your favorite podcasts by... sharing, downloading, reviewing, and giving it at 5 star rating. 

What does it take to build, tune, and drive a monster Mitsubishi Evolution VIII with a 4.1-litre VR38DETT putting down 1065 hp to all four treads — on pump gas, no less? On this episode of Tuned In, we talk to the Armchair Tuner to find out.Use “EVO100” to get $100 off HPA's Tuning Starter Package: https://hpcdmy.co/tuningpackagebConrad Bradley has been building fast cars and bikes for a long time, although he currently works outside of the automotive industry in the nuclear field. Conrad couldn't tell us much about his current work projects for obvious reasons, but when it comes to his many interesting automotive projects, he's an open book.Over the years, Conrad's built many fast cars — from rapid Subarus, to even faster Evos, to an immaculate Beams-powered AE86 — we discuss all those builds in this conversation, but it's his one-of-a-kind Evolution VIII that we're most interested in.We dive deep into this build with Conrad, digging into the big questions, like:Why ditch the 4G63?Why the VR38DETT?How is it still 4WD?What was the hardest part of the build and how was it dealt with? Has it changed how the car drives?Why even build something as unique as this car in the first place?This is a fascinating look into a very serious build that presented a lot of problems, requiring unique solutions.Further into the conversation, we also discuss the challenges of owning and operating a tuning shop, reflashing challenges, Evo strengths and weaknesses, and much more. This is a great listen for anyone interested in thinking outside the box when it comes to building cars and going fast. Follow Conrad here:IG: @armchairtunerFB: Armchairtuner YT: Armchair TunerDon't forget, you can use “EVO100” to get $100 off HPA's Tuning Starter Package: https://hpcdmy.co/tuningpackagebTime Stamps:4:25 How did you form an interest in cars?14:01 How did you end up owning a tuning shop?20:43 Pros and cons of owning a tuning shop.27:50 Transition from motorbikes to cars.29:23 Why JDM vehicles?34:05 Reflashing JDM vehicles.39:29 Was it Subaru's reliability issues that drove you to the Mitsubishi platform?43:04 Toyota AE86.58:03 Back into the Mitsubishi world? Evo X.1:04:17 Manufacturers making it difficult for us to tune modern engines.1:09:34 What came after the Evo X?1:11:31 Building an Evo for drag racing.1:24:36 How did the Evo GT-R come about?1:27:36 What was involved in fitting the VR38?1:34:49 What is the transmission?1:41:22 Motec M1 custom package for 4wd setup1:47:10 How much does it weigh with the VR38?1:48:06 What was the goal for the VR38?1:56:07 Are you running PDMs?1:58:50 Are you using the data from all your sensors for anything in particular?2:00:02 Is the Evo GT-R finished?2:06:09 Final 3 questions.

My client recommended I reach out to Ronan due to the valuable work he is doing in building connection. Ronan is a facilitator whos work with groups involves a variety of methodologies like positive psychology, sports psychology, CBT, Compassionate Inquiry, PDMS, and the Hero's Journey.  Working with prison inmates, high performance athletes, top tier corporate groups and more, his ability to create a safe and energetic space to explore connection, growth and express vulnerability is simply phenomenal. Ronan discusses our universal expression of human needs, the power of connection, the common threads that connect elite athletes and convicted criminals and so much more in this fantastic conversation. Learn more about Ronan here       Connect with me on IG: @conorosheafit To learn more about my online coaching program for men over 30: Click here

Ronan Conway is a facilitator whos work with groups involves a variety of methodologies like positive psychology, sports psychology, CBT, Compassionate Inquiry, PDMS, and the Hero's Journey. Working with prison inmates, high performance athletes, top tier corporate groups and more, his ability to create a safe and energetic space to explore connection, growth and express vulnerability is simply phenomenal. Ronan discusses our universal expression of human needs, the power of connection, the common threads that connect elite athletes and convicted criminals and so much more in this fantastic conversation. Prymal: ⁠@prymalpro⁠ Dan: ⁠@thedancampion⁠ Ronan: @conway.ronan Get your FREE copy of 20 Books and Podcasts to Change Your Life: ⁠https://mailchi.mp/prymal/bookspodcasts

Global Product Management Talk is pleased to bring you the next episode of... Product Mastery Now with host Chad McAllister, PhD. The podcast is all about helping people involved in innovation and managing products become more successful, grow their careers, and STANDOUT from their peers. About the Episode:  Today we are talking about the skills product managers need to grow their careers. To help us, Neha Bansal  is with us. She is the Head of Merchant Growth and Monetization for Google's B2B ecommerce business, where she is leading efforts to build the next $1B+ B2B business for the company. Before joining Google, Neha worked as a Management Consultant at Essex Product Consulting, where she helped organizations build products. Outside of her day job, she has guided many PdMs in reaching their career goals, and consequently, has good insights about the skills they need.

Innovation technologique Liliane Bettencourt (2022-2023) - Lydéric BocquetCollège de FranceAnnée 2022-2023Colloque - La nanofluidique à la croisée des chemins : New Approaches in Nanofluidics: Carbon Nanotubes Mechanical ResonatorsI will present our work in the direction of combining mechanical resonator and nanofluidic channel with a carbon nanotube.First, I will discuss how mechanical resonators will allow to answer, experimentally, open questions in the nanofluidic community about the structure of water, the phase diagram and the mechanism behind the fast flow observed in carbon nanotube. Second, I will show that SU8 microfluidic allows to combine antagonist worlds of fluidics (ambient pressure) and mechanics (secondary vacuum). Such devices can sustain large water pressure up to 5 bars and do not degrade over time. Porosity of SU8 is equal or better to PDMS, the standard in fluidics. Moving to carbon nanotube nanomechanical resonators, I will show that they exhibit exquisite mass sensitivity down to 70 yg, even at room temperature. This feature is observed in several devices, making it a reliable asset. I will discuss the limitations to the sensitivity in terms of thermomechanical noise, frequency fluctuations, etc.Finally, I will demonstrate that electrons in carbon nanotubes can distinguish water adsorbed on the surface of the nanotube from water confined inside the nanotube.Again, this feature is reproducible in several devices and independent of the metallicity of the nanotube.Adrien NouryAdrien Noury received his PhD in Physics (Photonics and Material Sciences) in 2014 from Univ. Paris Sud, on carbon nanotubes hybrid photonics. He then joined the group of Adrian Bachtold in ICFO Barcelona to work on quantum electromechanics with graphene drums, and later Helium superfluids on nanotube mechanical resonator. Since 2017 he is CNRS researcher in L2C, Montpellier, where he started and led the Nanomechanics group. His research focuses on harnessing the exceptional sensitivity of nanotube mechanical resonators in order to adress challenging questions in Physics.

Diese Folge ist eine tiefe Verbeugung vor der Leistung der Krankenhaus-IT. Geplant war die Folge von Christian und Renato als ein kurzer Überblick über die verschiedenen Systeme, die im Krankenhaus neben KIS, PDMS, RIS und PACS verwaltet werden müssen. Als wir dann aber feststellen mussten, WIE VIELE verschiedene (teilweise sehr komplexe) IT-Systeme in einem Krankenhaus existieren, ist uns selbst ein wenig die Kinnlade heruntergefallen. Und der Überblick, den wir in dieser Folge geben ist noch nicht mal ansatzweise vollständig. Natürlich kann man bei einer solchen Menge thematisch nicht allzu sehr in die Tiefe gehen. Aber zu vielen der Systeme gibt es bereits Podcast-Folgen, sodass man Details auch dort anhören kann. Am Ende sollte auf jeden Fall der Eindruck zurück bleiben: So eine Krankenhaus-Systemlandschaft ist ganz schön vielfältig und aufregend!

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.14.536862v1?rss=1 Authors: Carnicer-Lombarte, A., Boys, A., Guemes, A., Gurke, J., Velasco-Bosom, S., Hilton, S., Barone, D. G., Malliaras, G. G. Abstract: Implantable devices interfacing with peripheral nerves exhibit limited longevity and resolution. Poor nerve-electrode interface quality, invasive surgical placement and development of foreign body reaction combine to limit research and clinical application of these devices. Here, we develop cuff implants with an ultraconformable design that achieve high-quality and stable interfacing with nerves in chronic implantation scenarios. When implanted in sensorimotor nerves of the arm in awake rats for 21 days, the devices recorded nerve action potentials with fascicle-specific resolution and extracted from these the conduction velocity and direction of propagation. The ultraconformable cuffs exhibited high biocompatibility, producing lower levels of fibrotic scarring than clinically equivalent PDMS silicone cuffs. In addition to recording nerve activity, the devices were able to modulate nerve activity at sub-nerve resolution to produce a wide range of paw movements. The developed implantable devices represent a platform enabling new forms of fine nerve signal sensing and modulation, with applications in physiology research and closed-loop therapeutics. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

A cidade da Serra passa a contar com um um novo Plano Diretor Municipal. É o chamado "Plano Diretor Municipal Sustentável" (PDMS) cuja expectativa é trazer ordenamento às questões ambientais e sustentáveis da cidade. A sua revisão passa a ser realizada em cinco anos e não em 10, como anteriormente, "evitando que fique obsoleto diante de tantas mudanças que ocorrem no cenário de um grande município como a Serra", segundo a administração municipal. O plano aponta áreas melhor infra-estruturadas com rede esgoto, escolas, creches e asfalto, priorizando um melhor adensamento, que é o maior número de pessoas por metro quadrado.

This is the third series of Agile Framework Fight night. This fight night was hosted in Seattle by Beyond Agile. Like the first Agile Framework Fight Night, we brought together another winning panel of experts to represent the frameworks of DA, Fast Agile, LeSS, and SaFE. Agile Framework Fight Night, the SECOND SERIES happened at Beyond Agile, transmitted from Seattle. You can find Beyond Agile at Meetup.com here: https://www.meetup.com/BeyondAgile/ The expert panelists are: Ricardo “Dad of Doom” Garcia from Team DA This “Dad of Doom” has over 30 years of industry experience and has implemented and managed numerous software projects using Agile Practices for Fortune 500 companies. His work has been featured in white papers, cover stories in magazines, and is a frequent speaker at conferences and Agile expert panels. He is the organizer behind Seattle Disciplined Agile Meetup: https://www.meetup.com/Seattle-Disciplined-Agile-Meetup/ Ron Quartel AKA "Crocodile Ron-dee" Software Crafter, Disruptor, Pioneer and Intrapreneuer. On a mission to unleash the human spirit in the workplace. Founder of FAST Agile. https://www.fastagile.io Viktor "the Simplifier" Grgic Viktor is an Agile Coach, software developer and Certified LeSS trainer with 17 years of experience in delivering enterprise systems and Agile adoptions. He worked first 15 years in The Netherlands, and since 2013 in Hong Kong. https://less.works/profiles/viktor-grgic Barry Smith, the Nexus Knight Is a member of Unify's Lean-Agile practice, and committed to helping product teams to enjoy a better way of working and delivering exceptional value to their customers. His over 25+ years of working in technology has shown him that innovation can be fostered anywhere, from startups to Fortune 500 firms. Lancer “Unkind” Kind, moderating “Unkind” lives in Kirkland, and loves nothing more than writing micro tested software. For the last five years he has delivered consulting services in China, India, as well as the USA. He's a publishing author of science fiction and Agile Noir, a project management business novel. He's podcasting at Agile Thoughts, 敏捷理念 (the Chinese edition of Agile Thoughts), and SciFi Thoughts. His Agile at scale business novel is “continuously delivered” via Lean Pub at: https://leanpub.com/AgileGrande Here is a link to this Beyond Agile event in Meetup which contains comments about the fight night: https://www.meetup.com/beyondagile/events/286465281/ You can listen to the first and second Bouts of Agile Framework Fight Night series here: https://agilenoir.biz/en/agilethoughts/agile-framework-fight-night/ Chat record from Bout 3 of Agile Framework Fight Night Jon Jorgensen to Everyone (10:04 PM) I know Niels Pflaeging. Would you like me to ask him if he'd like to speak to this group? Aki Namioka to Everyone (10:05 PM) Where is Niels Pflaeging located? Jon Jorgensen to Everyone (10:06 PM) Germany Ricardo to Everyone (10:08 PM) For Jobs at Costco pls send me an email at ricardo.garcia@costco.com shama to Everyone (10:08 PM) Ron Lichty to Everyone (10:10 PM) Enterprise Agile Global Community: Dennis Stevens: Agile for Execs: https://us02web.zoom.us/j/89071064881?pwd=a1NoY2ptN3BudGd1OGNINXNtQ0ZYQT09 Josh Novajosky to Everyone (10:11 PM) Amazing shirt Ron Barry L Smith to Everyone (10:18 PM) “LeSS”, of course, refers to “Lightweight Similarity to Scrum" - really, they copied all their good ideas from Nexus. Ron Lichty to Everyone (10:24 PM) I thought I heard Paige Watson describe the FAST meeting as five PdMs bringing in the five priorities for the cycle? Is a “nexus” essentially what others are calling a "tribe”? Barry L Smith to Everyone (10:27 PM) Yes, similar to tribe or ART (Agile Release Train) - the group of teams that are collaborating in developing & delivering a Product Backlog. Jon Jorgensen to Everyone (10:29 PM) Seems like HUGE enterprises would have HUGE concerns (problems) to resolve for the people of the world and inside the organization. Silpa to Everyone (10:31 PM) Our scrum team is of 16 members. We formed mini scrum teams of 4 in each team with 1 PO, 1 SM, making sure we have a process expert supporting each mini scrum team. Jon Jorgensen to Everyone (10:31 PM) The crafting of experiments to see if hardware/software or other kinds of “works” is what runs through an organization. Which of the Frameworks are predicated on the assumption that software products are the resolution of these concerns? Barry L Smith to Everyone (10:32 PM) Jon, are you essentially asking, “Is experimentation a core element of your framework”? Jon Jorgensen to Everyone (10:32 PM) yes Me to Aki Namioka (Direct Message) (10:33 PM) What is our "finish" time? One hour or? Jon Jorgensen to Everyone (10:33 PM) And “What kind of professionals are involved in the experiment?” Barry L Smith to Everyone (10:34 PM)

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.11.07.515431v1?rss=1 Authors: Girardin, S., Ihle, S. J., Menghini, A., Krubner, M., Tognola, L., Duru, J., Ruff, T., Fruh, I., Muller, M., Vörös, J. Abstract: Novel in vitro platforms based on human neurons are needed to improve early drug testing and address the stalling drug discovery in neurological disorders. Topologically controlled circuits of human induced pluripotent stem cell (iPSC)-derived neurons have the potential to become such a testing system. In this work, we build in vitro co-cultured circuits of human iPSC-derived neurons and rat primary glial cells using microfabricated polydimethylsiloxane (PDMS) structures on microelectrode arrays (MEAs). Such circuits are created by seeding either dissociated cells or pre-aggregated spheroids at different neuron-to-glia ratios. Furthermore, an antifouling coating is developed to prevent axonal overgrowth in undesired locations of the microstructure. We assess the electrophysiological properties of different types of circuits over more than 50 days, including their stimulation-induced neural activity. Finally, we demonstrate the effect of magnesium chloride on the electrical activity of our iPSC circuits as a proof-of-concept for screening of neuroactive compounds. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

It's It's “In the News…” a look at the top diabetes stories and headlines of the past seven days. This week: a troubling new study about how many people with diabetes ration insulin, a new study looks at OpenAPS compared to traditional pumps, more research on Beta Bionics' iLet pump, an old diabetes drug might help in the fight against dementia, and more! Learn more about the T1D Exchange: https://t1dexchange.org/stacey/ Check out Stacey's book: The World's Worst Diabetes Mom! Join the Diabetes Connections Facebook Group! Sign up for our newsletter here Episode Transcription Below (or coming soon!) Please visit our Sponsors & Partners - they help make the show possible! *Click here to learn more about OMNIPOD* *Click here to learn more about AFREZZA* *Click here to learn more about DEXCOM* Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines of the past seven days. XX In the news is brought to you by T1D Exchange! T1D Exchange is a nonprofit organization dedicated to improving outcomes for the entire T1D population. https://t1dexchange.org/stacey/ XX A new study shows nearly 1 in 5 adults in the U.S. with diabetes either skipped, delayed or used less insulin than was needed to save money. That comes out to roughly 1.3 million adults, or 16.5% of those who need insulin. The findings were based on data from the 2021 National Health Interview Survey, which is conducted annually by the Centers for Disease Control and Prevention and which interviews tens of thousands of Americans about their health-related experiences. It was the first time that the CDC had included questions about insulin use, though concerns about sky-high insulin prices have been reported for years. Starting Jan. 1, the Inflation Reduction Act, signed into law by President Joe Biden in August, will cap the monthly cost of insulin at $35 for seniors on Medicare. The bill, however, will leave out millions of Americans with private health insurance as well as those who are uninsured. It was also found to be more common among people with type 1 diabetes, at 18.6%, compared to those with type 2 diabetes, at 15.8% https://www.nbcnews.com/health/health-news/insulin-prices-many-adults-diabetes-ration-insulin-study-finds-rcna52287?cid=sm_npd_nn_tw_ma XX New islet cell transplant study looks very promising. Long term outcomes of two phase 3 clinical trials shows many patients didn't need insulin to maintain their blood sugar for up to eight years. It also showed that a new approach required fewer transplants than typical and was exceedingly safe. These trials included people who had kidney transplants and showed islet cell transplants for those people was safe and effective. 75 percent who initially were able to come off insulin therapy, more than half maintained total insulin independence, meaning they needed no additional insulin injections throughout the years of follow-up. https://www.pennmedicine.org/news/news-releases/2022/october/new-islet-transplant-method-leads-to-insulin-independence XX Study out of New Zealand looked at DIY diabetes tech and compared to some commercial offerings. Not sure what they were tyring to prvoe here because they looked at a closed loop system OpenAPS and compared it to a regular old pump and CGM system with no automation. No surprisingly, the people with type 1 in the AID group had much more time in range – about 14 percent more – than those using a standalone pump and CGM. No severe lows or DKA in either group. But these days, IMO, looking at an automated insulin delivery system to a pump and CGM that don't communicate is like comparing apples and chain saws. https://www.medtechdive.com/news/do-it-yourself-artificial-pancreas-diabetes/633888/ XX More good news for the iLet Bionic Pancreas. A clinical trial, conducted at 16 clinical sites across the United States, enrolled 326 participants ages 6 to 79 years who had type 1 diabetes and had been using insulin for at least 1 year. Participants were randomly allocated to a treatment group using the bionic pancreas or a standard-of-care control group that continued with their pre-trial method of glucose monitoring and insulin dosing. In participants using the bionic pancreas, A1C improved from 7.9% to 7.3%, yet remained unchanged among the control group. The iLet doesn't use carb counting – just meal announcements and it sets basal rates with just the user's body weight. It's currently in front of the US FDA, awaiting approval. XX Insulet issued an urgent medical device correction on Monday related to battery problems with a component of its Omnipod DASH system. The device uses a wearable insulin pod that's controlled by a personal diabetes manager (PDM), a smartphone-like device that does the calculations for bolus insulin doses. Insulet plans to replace the PDMs for all of its current Omnipod DASH users globally, incurring an aggregate charge of $35 million to $45 million, J.P. Morgan Analyst Robbie Marcus wrote in a Monday research note. Insulet said it received reports of some Omnipod DASH users having battery problems with their PDM devices, including the battery swelling, fluid leaking from the battery, and in rare cases, extreme overheating. In a letter to users, the company said it plans to ship updated devices to all current Omnipod DASH customers in the coming months. The battery issue applies to all of Insulet's Omnipod DASH PDMs, but the likelihood of problems may increase if the device has been in use longer than 18 months. Charging the device to a full battery and leaving it on the charger overnight also increases the risk. So far, Insulet said it has not received reports of any injuries related to the battery issues. The company advised patients to monitor their PDMs for battery problems, including a bulging back cover and the device losing its charge very quickly, overheating or emitting an odor. If patients notice any of these problems, they should not charge the device, stop using the system and switch to a backup insulin plan as soon as they can. Users can also contact Insulet for a temporary replacement device. https://www.medtechdive.com/news/insulet-battery-problems-omnipod-dash/634275/ XX MDT) announced today that it introduced a new diabetes management program for users of the MiniMed 770G insulin pump. The medtech giant calls the new program My Insights. It designed it exclusively for individuals using the MiniMed 770G hybrid closed-loop insulin delivery system. Using an individual's data, My Insight provides personalized tips, trends and reminders to help customers manage their diabetes. Its personalized recommendations come through via monthly emails with educational content. Medtronic aims to make the content relevant based on what the individual experiences. Medtronic said it represents the first diabetes management program to go beyond “generalized tips.” Instead, it offers personalized suggestions using data from the integrated insulin pump system. The company said it made My Insights available in the U.S. to anyone using MiniMed 770G. https://www.drugdeliverybusiness.com/medtronic-launches-diabetes-insights-program-for-minimed-users/ XX Some countries are seeing shortages of Ozempic, a weekly injectable meant for people with diabetes but can be prescribe off label for weight loss. Demand has gone way up since some Tik Tok and social media influencers have shared Ozempic as a weight loss drug. Diabetes groups and especially Australian advocacy groups have advised doctors to limit prescribing the drug to people with Type 2 diabetes. https://www.abc.net.au/news/2022-10-17/ozempic-weight-loss-demand-type-2-diabetes-drug-shortage/101542226 XX Back to the news in a moment but first.. The T1D Exchange Registry is a research study conducted online over time, designed to foster innovation and improve the lives of people with T1D. The platform is open to both adults and children with T1D living in the U.S. Personal information remains confidential and participation is fully voluntary. Once enrolled, participants will complete annual surveys and have the opportunity to sign up for other studies on specific topics related to T1D. The registry aims to improve knowledge of T1D, accelerate the discovery and development of new treatments and technologies, and generate evidence to support policy or insurance changes that help the T1D community. By sharing opinions, experiences and data, patients can help advance meaningful T1D treatment, care and policy. The registry is now available on the T1D Exchange website and is simple to navigate, mobile and user-friendly. For more information or to register, go to www.t1dregistry.org/stacey XX XX XX New research shows an older drug for type 2 might help reduce the risk for dementia. People with diabetes are at higher risk of developing dementia. These researchers looked though 500-hundred thousand past medical records and found that an older class of type 2 diabetes medication known as glitazones helps reduce a person's dementia risk by 22%. These reerahres say its very promising but they want to see more real world study and also combine glitazones with other types of treatments https://www.medicalnewstoday.com/articles/type-2-diabetes-drug-may-help-lower-dementia-risk-by-22 XX On the podcast next week.. Kerri Sparling from SixUntilMe The past episode was all about teens and type 1 – a deep dive into why teen retreats work from the people who organize a great one.. and how adults with type 1 still use the lessons they learned as teens. Listen wherever you get your podcasts That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Why should you be concentric-twisting your wiring? What tools should you buy if you're looking to build a harness? And when is it actually OK to use a soldering iron? This week on Tuned In, Matt Sanderson from Level Motorsport Wiring aims to answer these questions and many more. Use ‘PODCAST75' for $75 off your first HPA course here: https://hpcdmy.co/hpa-tuned-inMatt is a seasoned expert when it comes to professional-level motorsport wiring — his work is so good, we've been using his Instagram as inspiration for our own projects for a good while now. Based in the UK, Matt has a background in general mechanical work, which eventually transitioned into auto-electrical before the decision was made to start a company — Level Motorsport Wiring — that specialised in the high-end side of the wiring game.In this conversation, Matt and Tuned In host Andre Simon explore the ins and outs of designing and building a high-end motorsport harness, following the process from start to finish. There's a lot that goes into the planning and documenting side of the job that may not be immediately obvious. That, combined with some great wiring tips and tricks, make this an unmissable episode for anyone that has an interest in wiring, PDMs, "milspec", and motorsport electronics in general. Follow Matt here:IG: @levelmsw_FB: Level Motorsport WiringTK: @LevelMSWYT: Level Motorsport WiringWWW: levelmotorsportelectronics.co.ukWant to learn more about motorsport wiring? Claim your spot for the next FREE lesson: https://hpcdmy.co/wireb

This week, please join author Guest Host Mercedes Carnethon, Author Brian Bergmark, and Associate Editor Parag Joshi as they discuss the article “Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70.” Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. We're your co-host. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center in Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor, Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Well Carolyn, this week's feature, non-high density lipoprotein cholesterol levels in statin treated patients with elevated cholesterol. We're going to hear from the TRANSLATE-TIMI 70 study. But before we get to that, how about we grab a cup of coffee and discuss some of the other articles in the issue? Would you like to go first? Dr. Carolyn Lam: I would. And by the way, that feature is going to be all exciting. It was discussed at the American College of Cardiology. But okay, how about from cholesterol to vitamins? Let's start with the Greg quiz. Greg, which vitamins have been associated with arterial calcification? Is it A, B, C, D, E? Dr. Greg Hundley: I'm going to pick E and K. Dr. Carolyn Lam: You're smart. Indeed. Vitamin K2, also known as menaquinone-7 is the most effective co-factor for the carboxylation of proteins involved in the inhibition of arterial calcification. Furthermore, combined low vitamin K and low vitamin D have been associated with increased all-cause mortality risk. And so, today's paper is from Dr. Diederichsen from Odense University Hospital in Denmark and colleagues really present the first double-blind, randomized controlled trial to test whether vitamin K2, a drug-targeting processes of calcification in addition to vitamin D, could slow the progression of aortic valve calcification and stenosis. So, in a randomized double-blind multicenter trial, men from the community with an aortic valve calcium score above 300 arbitrary units on cardiac non-contrast CT were randomized to daily treatment with 720 micrograms of vitamin K2 plus 25 micrograms of vitamin D or matching placebo for 24 months. And the primary outcome was the change in aortic valve calcium score. Dr. Greg Hundley: Carolyn, so menaquinone-7 and aortic valve score. So, what were the results? Dr. Carolyn Lam: Menaquinone-7 had no major effect on the progression of aortic valve calcification as assessed by CT or echo. High-dose menaquinone-7 was, however, safe and well tolerated. Now, some limitations is that this external validity is limited to men aged 65 to 74 with aortic valve calcification scores of greater or equals to 300 arbitrary units. Thus, caution is needed if we extrapolate these findings and other pathways need to be explored in order to identify an effective therapy for this unmet clinical need. Dr. Greg Hundley: Wow, very nice Carolyn. Well, my first article comes to us from Dr. Michael Laflamme from the University Health Network. And Carolyn, human pluripotent stem cell-derived cardiomyocytes or hPSC-CMs exhibit promise for application in cardiac regeneration, but their translational potential is limited by an immature phenotype. So Carolyn, this research team hypothesized that large scale manufacturing of mature hPSC-CMs could be achieved via culture on polydimethylsiloxane, and we're going to call that PDMS, lined roller bottles and that the transplantation of these cells would mediate better structural and functional outcomes then with conventional immature hPSC-CMs populations. Dr. Carolyn Lam: Oh, that's neat, Greg. So, what did they find? Dr. Greg Hundley: Right, Carolyn. So, these authors demonstrated the economic generation of greater than one times 10 to the eighth mature hPSC-CMs per PDMS line roller bottle. And compared to their counterparts, PDMS matured hPSC-CMs exhibited increased cardiac gene expression and more mature structural and functional properties in vitro. More importantly, intracardiac graphs formed with PDMS matured myocytes showed greatly enhanced structured alignment, better host graft electromechanical integration, less pro arrhythmic behavior, and greater beneficial effects on contractile function. So in summary, Carolyn, this team describes practical methods for the scale generation of mature human pluripotent stem cell-derived cardiomyocytes and provide the first evidence that the transplantation of more mature cardiomyocytes yields better outcomes in vivo. And there's a wonderful editorial by Professor Murray entitled Flexing Their Muscles: Maturation of Stems Cell-Derived Cardiomyocytes on Elastomeric Substrates to Enhance Cardiac Repair. Dr. Carolyn Lam: Wow! That's really significant. Thank you, Greg. Well, the next paper is the largest genome-wide association meta-analysis of plasma ACE2 levels in over 28,000 individuals. And this is from Dr. Xia Chen from Fudan University and Dr. James Wilson from University of Edinburgh in UK, and their colleagues. And guess what, it focuses on severe acute respiratory syndrome coronavirus 2, the etiologic agent of COVID 19. And we know that that enters human cells using the ACE2 protein as a receptor. ACE2 is thus key to the infection and treatment of the coronavirus. ACE2 is highly expressed in the heart, respiratory and gastrointestinal tracts, playing important regulatory roles in the cardiovascular and other biologic systems. Dr. Greg Hundley: Wow, Carolyn. ACE2, and also a very important topic here with SARS-COVID-2. So, what did they find? Dr. Carolyn Lam: First, the overall heritability of ACE2 level is 16% of which 30% can be explained by 10 protein quantitative trait loci identified in this study. ACE2 level is genetically correlated with both COVID-19 and cardiovascular. Elevated ACE2 levels show a causal relationship with COVID-19 severity, hospitalization and infection as shown by Mendelian randomization analyses. ACE2 regulatory variants are enriched on DNA methylation sites in immune cells. Dr. Greg Hundley: Wow, Carolyn. So, elevated ACE2 and a causal relationship with COVID-19 severity. So tell us, what are the clinical applications of this really nice study? Dr. Carolyn Lam: The causal evidence of ACE2 suggests that pharmacological inhibition of circulating ACE2 may be a promising approach for treating COVID-19 or its comorbidities. Transcription factors that play essential roles in ACE2 generation could provide alternative paths to pharmacological modulation of ACE2 plasma levels. The genetic correlations between ACE2 and both COVID-19 and cardiovascular disease imply that the cardiovascular complications seen in COVID-19 patients may be intrinsic to the disease and mechanically or/and mechanistically-driven by ACE2. Isn't that neat? Dr. Greg Hundley: You bet, Carolyn. Boy, what an exciting issue. And we've got other articles in this issue. Dr. Carolyn Lam: Yeah. Now, let me start this time. There's an exchange of letters between Drs. Duan and Chang regarding the article “Therapeutic Exon Skipping Through a CRISPR-Guided Cytidine Deaminase Rescues Dystrophic Cardiomyopathy in Vivo.” There's a Perspective piece by Dr. Morris, “The Updated Heart Failure Guidelines: Time for a Refresh.” Love that piece! There's an AHA Update piece (AHA President's Page) by Dr. Elkin on The Road to Equity in Brain Health, and ECG challenge by Dr. Kolominsky, Electrical Extremists in a Critically ill Patient, and an On My Mind Paper by Dr. Paulus entitled “Border Disputes Between Heart Failure Phenotypes.” Dr. Greg Hundley: Wow, Carolyn. And I've got two Research Letters. The first from Professor Groeneveld entitled “Prevalence of Short-Coupled Ventricular Fibrillation in a Large Cohort of Dutch Idiopathic Ventricular Fibrillation Patients.” And then a second Research Letter from Professor Yamashita entitled “Single Cell RNA Sequence Reveals a Distinct Immune Landscape of Myeloid Cells in Coronary Culprit Plaques Causing Acute Coronary Syndrome.” Well Carolyn, now, we get to go onto our feature, vupanorsen on non-high-density lipoprotein cholesterol levels and catching up with TIMI 70. Dr. Carolyn Lam: Let's go. Dr. Mercedes Carnethon: So, good morning listeners. I'm really pleased to invite you to this episode of our Circulation on the Run podcast. For those of you who don't hear me often, I'm stepping in as a guest host today. My name is Mercedes Carnahan from the Northwestern University Feinberg School of Medicine. And I'm really excited to be joined today by Dr. Brian Bergmark, and associate editor, Dr. Parag Joshi. And we will have today Dr. Bergmark discussing his new article published with us on the effects of vupanorsen on non-HDL cholesterol levels in the TRANSLATE-TIMI 70 trial. We're really thrilled to have you with us here today, Brian, to talk about the really important findings coming from this trial. So to start us off, just tell us, what did you find? Dr. Brian Bergmark: Great. Thank you so much. It's really a pleasure to be here and I'm grateful for the opportunity. So, in the big picture, despite numerous agents to reduce lipid-mediated cardiovascular risk, obviously, residual risk remains and there are novel targets to address that risk. One of them is angiopoietin-like 3, which is a protein made in the liver. Angiopoietin-like 3 or ANGPTL3 inhibits lipoprotein lipases among other lipases, and thereby interferes with metabolism of triglyceride-rich lipoproteins. And so, the idea here was that if ANGPTL3 could be inhibited that LPL or lipoprotein lipase function could be augmented and metabolism of these lipoproteins could be augmented. And so, what we did is we took patients with an elevated non-HDL cholesterol, at least 100 milligrams per deciliter, and elevated triglycerides, 150 to 500 milligrams per deciliter, and randomized them to placebo or one of seven doses of vupanorsen, which is an antisense oligonucleotide, which inhibits the synthesis of ANGPTL3 in the liver. We then follow them to see what the impact was on their non-HDL cholesterol, as well as other lipid parameters through 24 weeks. Dr. Mercedes Carnethon: Thank you so much. It's a wonderful design, and I'm really excited to hear a little bit more about what you found. Dr. Brian Bergmark: Great. So, the primary endpoint was the change in non-HDL cholesterol from baseline to 24 weeks. And we did find that all vupanorsen regimens reduced non-HDL cholesterol in a statistically significant manner. The magnitude of that effect was up to 27.7% in one of the dose arms or about 28%. We also saw a statistically significant reductions in the target ANGPTL3 up to about a 95% reduction in the highest dose arm, as well as statistically significant reductions in triglycerides at all of the dose regimens. The effect on LDL cholesterol and on apolipoprotein B or apo B was variable across regimens and only statistically significant in a few of the dose arms. We also found several safety signals. One, there appeared to be higher rates of injection site reactions in the skin at higher total monthly doses. We also found higher rates of elevation in liver enzymes, AST and ALT at higher total monthly doses. And we also found significant increases in hepatic fat fraction or the fat content of the liver at higher total monthly doses. Dr. Brian Bergmark: In the end, we found that while statistically significant, the magnitude of the reduction in non-HDL cholesterol was modest as was the reduction in apo B. And so, the goal here was to find a dose that might have a reduction of a magnitude that would be clinically meaningful for cardiovascular risk reduction. We were underwhelmed by the magnitude of that reduction, and then it was paired with these safety signals, which if there's interest, we could get into more detail in our thinking about why those occurred, what the implications are, but suffice it to say that there were medically meaningful safety concerns paired with a modest reduction in non-HDL cholesterol. Dr. Mercedes Carnethon: Thank you for that excellent summary. Before I turn it over to the associate editor, I read this with great interest, and in particular, looking at one of the first figures in the paper, which is demonstrating the adjusted change at 24 weeks across different doses and based on how frequently the doses were given the four week as compared with the two week. And one thing that really stood out to me was the clear dose response with the four week regimens with the higher doses appearing to demonstrate the greatest reductions but a less clear signal with the two week regimens. Do you have any hypotheses about why these patterns appeared so different? Dr. Brian Bergmark: Yeah. It's a great question. So, the responsiveness of this is something of interest here I think. So, if you look at the effect of the drug on its target, ANGPTL3, there is a very clear dose response, so there's no doubt that higher doses were impacting the target ANGPTL3 to a greater extent. So, one of the most direct effects would be on triglycerides, one of the most direct lipid effects, and that appears pretty close to a dose response relationship within each of these frequencies of administration. But once you start getting to non-HDL cholesterol, it starts to break down a bit. And is it simply because of random chance or is there actually something distinct going on with how the lipids are being metabolized? Dr. Brian Bergmark: That is something we are diving into. So, the hope would be that we actually reduce apo B, the number of these actually circulating lipoproteins as has been demonstrated with the monoclonal antibody. It's possible that with this other different mechanism in the antibody, this antisense oligonucleotide, perhaps, we're simply shifting the content of these lipoprotein molecules and decreasing the triglyceride content but not actually meaningfully modifying the amount of apo B, LDL cholesterol. And that might be part of what we're seeing with the more muted relationship between dose and the effect on non-HDL cholesterol. I don't know for certain we are diving into this a bit more with other lipid fractions, et cetera. Dr. Mercedes Carnethon: Oh, well, thank you so much for that explanation. I know that a number of people, this was extremely well received when shared at the recent American College of Cardiology meetings, and so I was really thrilled to find that this was appearing in the journal circulation. So Parag, I'm really interested in hearing your perspectives on why we knew that this was certainly a priority paper for us. Dr. Parag Joshi: Yeah. Let me first start, Brian, congratulations. Fantastic work. And we were excited to receive the paper. I think really hard to pull off trials right now or in the last couple years, so kudos to you. And I echo the sentiments from Mercedes. This is great work. Really important space, the residual risk space I think is very important of course and is critical to moving forward with improving cardiovascular health. So, one of the big picture questions and as we get to this triglyceride-rich lipoprotein lowering space, certainly, there's strong associations with residual risk, but can we impact that risk? And here, we're starting to explore that. And I think when you think of the lipoprotein space, many of us are interested in what is the effect on these lipoproteins as opposed to the cholesterol content or the triglyceride content. And non-HDL cholesterol or apo B, clearly, the better, stronger markers for that risk, so we were really excited to see this paper.   Dr. Parag Joshi: And as Brian mentioned, unfortunately, not the strongest impact here on those measures. And I want to dive into that a little more because I think that carries significant implications for the space, and I'd love to hear your thoughts on that. But overall, really fantastic work. I think my first question really is around the apo B aspect of this and the less than anticipated lowering of those levels. You hinted at this in terms of, is this shuffling cholesterol and triglycerides across particles, or do you think this could be the mechanism by which this happens through ANGPTL3? You do inhibit the levels quite a bit. Did we just miss that... Is this not the right target? What do you think? Dr. Brian Bergmark: Yeah, it's a great question. I do think the target itself holds great promise. Obviously, a monoclonal antibody against this same target results in major reductions in apo B, LDL cholesterol, and the latter through a mechanism that is not really known but is not dependent on the LDL receptor, and therefore has real clinical utility that's approved for people with familial homozygous hypercholesterolemia. Beyond that, of course, in genetic studies, there's a clear association with loss of function in the ANGPTL3 gene and lower levels of all of these lipids, lower rates of coronary artery disease, et cetera. Dr. Brian Bergmark: So, I think it's not that this pathway is not promising and actually already being taken advantage of, I think it's that this particular agent acting through this mechanism was not able to achieve a necessary efficacy with reasonable safety. Some genetic data suggests that there is not actually a dose response between a reduction or loss of function in ANGPTL3 and reduction in apo B or lower levels of apo B and non-HDL cholesterol, but it really requires your complete elimination of ANGPTL3 function, which is probably, likely achieved with the monoclonal antibody. And so, even though we had quite large reductions with the antisense oligonucleotide, perhaps, we just didn't cross that threshold that's needed to modify the lipid panel in the way that would've been clinically meaningful. Dr. Parag Joshi: Yeah. I think that's fantastic as you allude to with evolocumab and the impact that has on apo B levels. I didn't think of it as a threshold effect, but that makes a lot of sense as maybe that just getting to that tipping point is where the issue is here. In terms of the liver signal, what were your thoughts on that? And is that something that we should expect to see in ASOs or do you think it's specific to this compound? Dr. Brian Bergmark: Yeah, I don't know. That was unexpected. Right, there are two liver signals and it's unclear how related they are. One is the inflammation of the liver as indicated by the elevation in enzymes, and then the other is the fat accumulation. So with respect to the fact, if anything, genetic data suggests perhaps loss of function in ANGPTL3 might result in lower rates of hepatic steatosis. In animal models, the antisense oligonucleotide reduces liver fat, and so there's, there was promise going into this that this could actually be beneficial for non-alcoholic fatty liver disease. And additionally, there's not data to suggest that the monoclonal antibody increases liver fat. So, there's not a lot to support this as being an on-target effect that by inhibiting ANGPTL3, by that pathway, the liver fat was increased. So, I think a reasonable person might wonder whether this was an off-target effect of the drug. Dr. Brian Bergmark: By what mechanism that occurred, I don't know, what the implications would be for other related agents, I don't know. And then similarly, the liver enzyme elevations, is that related to this? I'm not exactly sure, but also unexpected and I think off-target. But that sort of intrinsic to this mechanism of hepatic targeting, is this something we need to be worried about for other agents in this class or not? I don't know. Obviously, we can't answer that from this single study. We are going to dive into it a bit more to try to overlay patients with hepatic fat accumulation, liver enzymes, et cetera. Of course, both of those happen more at higher doses. How much we can really parse this? I'm not sure yet. Dr. Parag Joshi: Yeah. That's really fascinating. I think the appeal of this paper to the circulation audience is that you have a really exciting novel target and pathway to explore here but somewhat divergent results from what's existing in this space. And I think that raises a lot of questions, really interesting questions going forward for this space. For the ANGPTL3 pathway, what do you see there coming down the line or what are your thoughts on that going forward for this target and ways to approach risk related to it? Dr. Brian Bergmark: Yeah. Great. Thank you. Yeah. No, so I agree. I think moving into this other end of the spectrum of triglyceride-rich lipoproteins, et cetera, I think this is where we're headed and this is why we do the trial. We weren't expecting these things that's why you do this experiment, and this is what we found. So now, where do we go from here? So there are, of course, other ways beyond the monoclonal antibody of targeting ANGPTL3 specifically. There's siRNA, there is gene therapy being investigated. So, I think all of them hold an great promise. And of course, we will need to see as those therapies move along what the actual trials show. And then there are, of course, other pathways that are of interest, APOC3, for instance. So, I think there's a lot more in this space that's coming down the line. Dr. Parag Joshi: Yeah, absolutely. I think it's a really exciting space, and we're really happy to get this paper as one piece of that whole puzzle. So, thank you. Dr. Mercedes Carnethon: Yes. And I echo that as well. And as a methodologist myself, I'm always really pleased to see such well-designed studies. I think this was sophisticated in many aspects in testing different dosing and different timing of the dosing. And also, I'm really impressed by your inclusion criteria, particularly when I noted that 44% of the participants were female, and that you reported those stratum-specific effects. I just had a final question as we wrap up. You acknowledge a nominally significant interaction by sex and I see, for example, that it appears that the magnitude is larger possibly in the relatively smaller subset of females as compared with males. Is this something to pay attention to or do you think this is just some type of an artifact related to greater variability because the group is smaller? Dr. Brian Bergmark: Yeah, it's a good question. So, this is the burning question. We had no a priority reason to suspect that biologically and we are not adjusting for multiple testing in the key value of 0.04. So just to put my money down, I would say, I would guess it's random chance. We found it. It's worthy of looking into a bit more. There were, of course, the important implications for other drugs, et cetera. So, I think it's worth diving into as we will, but are we likely to uncover some biological difference? I doubt it. I wouldn't guess. There are other subgroups where I think at least upfront, you might expect there could be a difference. So, there are thoughts about insulin's effect on LPL. Could diabetes status have an interaction with the drug? I think though not statistically significant, it's also something worth looking into that group and the subfractions of the lipid panel and all of that stuff. So, I think it's all worth looking into but cautiously with the constraints. Dr. Mercedes Carnethon: Well, thank you so much for that explanation. And I've really enjoyed this discussion with you today, Brian, and you, Parag. I've certainly learned a lot and I'm really excited to see this excellent work coming out in the journal circulation. So, thank you very much for your time this morning and thank you to our listeners. Wrapping up this episode of Circulation on the Run. Dr. Greg Hundley: This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more, please visit ahajournals.org.

[Werbung] und zwar in eigener Sache: Nicht besetzte Stellen und nicht vorhandene Skills sind zwei der größten Hindernisse bei der der Digitalisierung im Krankenhaus. Verschärft wurde dieser Fachkräftemangel auch durch regulatorische Vorgaben wie das KHZG und die diversen TI-Projekte. Da wir Krankenhaus-IT-Wissen hier im Podcast seit über 6 Jahren behandeln, als Professoren sowieso an unserer Didaktik feilen und pandemiebedingt viele interaktive Lehrkonzepte ausprobiert haben, wollen wir bei diesem Problem des  Fachkräftemangels helfen und haben in Kooperation mit der Digital Avantgarde in den letzten 1,5 Jahren fleißig Lehreinheiten zu den wichtigsten Krankenhaus-IT-Themen erstellt. Begonnen haben wir mit dem Thema "Krankenhaus", das sich wiederum in Krankenhausprozesse (Klinischer Kernprozess, Auftragskommunikation, Pflegeprozess, Medikation, Abrechnung, OP-Management, Termin- und Ressourcenmanagement, Klinische Pfade, Reifegradmodelle ...) und Krankenhaussoftware (KIS, RIS, PACS, PDMS, Archiv ...) unterteilt. Ein weiterer, großer Block ist die "Interoperabilität" mit Kommunikationsstandards (HL7v2, FHIR, CDA, HL7v3 ...), Semantische Interoperabilität (OPS, ICD, LOINC, SNOMED CT, PZN, ATC..), Prozessuale Interoperabilität (IHE, DICOM) und passender Software (Kommunikationsserver). Abgerundet wird das Lehrangebot durch "Regulatorische Bedingungen" wie z.B. Patientenrechte, KHZG, TI usw. sowie Methodik (u.a. Projektmanagement, Anforderungsermittlung und -priorisierung, Agile Methoden). Shownotes: Digital Avantgarde Akademie WebseiteE-Mail an akademie@digital-avantgarde.de Auf der DMEA sind wir auch regelmäßig beim Stand der Digital Avantgarde, Meldet Euch einfach, wenn das Schulungsangebot für Euch interessant sein sollte.

丽莎老师讲机器人之土耳其比尔肯大学巴掌大的新型微型机器人欢迎收听丽莎老师讲机器人，想要孩子参加机器人竞赛、创意编程、创客竞赛的辅导，找丽莎老师！欢迎添加微信号：153 5359 2068，或搜索钉钉群：31532843。近日，土耳其毕尔肯大学的研究人员发明了一款微型四足机器人——SQuad。与现有微型机器人不同的是，SQuad用软材料制成，行动更加灵活，可以攀越其身高2.44倍的障碍，也能绕开障碍物。未来，SQuad或能用于检查狭小空间、在废墟中搜救等。土耳其毕尔肯大学的研究人员研究微型机器人已有将近10年时间，微型机器人有许多优点，比如所需材料较少、成本低廉、能够进入狭窄空间等。但是，现有微型机器人的缺点也比较突出。“他们的主要缺点之一是缺乏运动能力，特别是在不平坦地形上。”微型机器人的高度有限，运动时无法攀爬或避开障碍物，因此很容易在运动过程中被卡住。相比于微型机器人，软体机器人的运动性能更好。大多数软体机器人都是用气动执行器制造的。研究人员介绍：“这些气动执行器可以和软材料实现非常好的集成效果，但是它们需要一个压缩气源，这往往会使机器人变得笨重、或不允许无绳运动。研究团队试图将两种机器人的优点加以结合，制作出综合性能更好的机器人。首先，选用聚二甲基硅氧烷（PDMS）等软材料来增加微型机器人的“身体顺应性（body compliance）”，使其运动能力变强。通过使我们的微型机器人变得柔软，它们能够利用自己的身体顺应性越过障碍，就像昆虫、老鼠等生物系统那样。同时，微型机器人搭载常规执行器来实现小型化和无绳移动。经过尝试，研究人员制成了微型四足机器人SQuad。该机器人有手掌大小，装配了集成直流电动机的柔性C型腿，可以自由旋转。研究人员通过一系列试验评估了SQuad的性能，并将其与一个刚性材料制成的机器人进行比较。结果显示，SQuad的运动性能更好。SQuad能够爬过比其身高还高1.44倍的障碍物，但刚性机器人只能爬过其身高0.88倍的障碍物。研究人员认为，这是因为两款机器人身体顺应性的差异。在未来，SQuad可以在陆地上完成各种简单的任务。由于具备高度灵活性、身体顺应性和增强的穿越障碍能力，SQuad可以爬过狭小的开口及在非结构化或不平坦的地形上运动。研究人也对SQuad的应用表现出信心，“他们认为，通过在机器人背上加一个小型摄像机，我们可以将这种机器人用于检查目的；通过集成一个摄像机和麦克风，就可以将其用于在倒塌的建筑物下寻找幸存者。”结语：设计还在更新，或增加身体收缩机制土耳其毕尔肯大学研究人员推出的微型四足机器人集合了传统微型、软体机器人的优点，能够爬越身高2.44倍高的障碍物，未来或可应用于检查、救援等场景。此外，为了使SQuad能够应用于更多场景，研究人员还在继续更新设计，钻研能提升机器人步态和动作的技术及性能更好的新型聚合物。研究团队正在增加一个身体收缩机制，“（它能）使我们的机器人在通过比其横截面面积小的开口时，短暂地收缩身体，就像老鼠的行为那样。我们还在研究机器人的动力学模型，以便更好地理解微型机器人、软体机器人的运动。”

丽莎老师讲机器人之土耳其比尔肯大学巴掌大的新型微型机器人欢迎收听丽莎老师讲机器人，想要孩子参加机器人竞赛、创意编程、创客竞赛的辅导，找丽莎老师！欢迎添加微信号：153 5359 2068，或搜索钉钉群：31532843。近日，土耳其毕尔肯大学的研究人员发明了一款微型四足机器人——SQuad。与现有微型机器人不同的是，SQuad用软材料制成，行动更加灵活，可以攀越其身高2.44倍的障碍，也能绕开障碍物。未来，SQuad或能用于检查狭小空间、在废墟中搜救等。土耳其毕尔肯大学的研究人员研究微型机器人已有将近10年时间，微型机器人有许多优点，比如所需材料较少、成本低廉、能够进入狭窄空间等。但是，现有微型机器人的缺点也比较突出。“他们的主要缺点之一是缺乏运动能力，特别是在不平坦地形上。”微型机器人的高度有限，运动时无法攀爬或避开障碍物，因此很容易在运动过程中被卡住。相比于微型机器人，软体机器人的运动性能更好。大多数软体机器人都是用气动执行器制造的。研究人员介绍：“这些气动执行器可以和软材料实现非常好的集成效果，但是它们需要一个压缩气源，这往往会使机器人变得笨重、或不允许无绳运动。研究团队试图将两种机器人的优点加以结合，制作出综合性能更好的机器人。首先，选用聚二甲基硅氧烷（PDMS）等软材料来增加微型机器人的“身体顺应性（body compliance）”，使其运动能力变强。通过使我们的微型机器人变得柔软，它们能够利用自己的身体顺应性越过障碍，就像昆虫、老鼠等生物系统那样。同时，微型机器人搭载常规执行器来实现小型化和无绳移动。经过尝试，研究人员制成了微型四足机器人SQuad。该机器人有手掌大小，装配了集成直流电动机的柔性C型腿，可以自由旋转。研究人员通过一系列试验评估了SQuad的性能，并将其与一个刚性材料制成的机器人进行比较。结果显示，SQuad的运动性能更好。SQuad能够爬过比其身高还高1.44倍的障碍物，但刚性机器人只能爬过其身高0.88倍的障碍物。研究人员认为，这是因为两款机器人身体顺应性的差异。在未来，SQuad可以在陆地上完成各种简单的任务。由于具备高度灵活性、身体顺应性和增强的穿越障碍能力，SQuad可以爬过狭小的开口及在非结构化或不平坦的地形上运动。研究人也对SQuad的应用表现出信心，“他们认为，通过在机器人背上加一个小型摄像机，我们可以将这种机器人用于检查目的；通过集成一个摄像机和麦克风，就可以将其用于在倒塌的建筑物下寻找幸存者。”结语：设计还在更新，或增加身体收缩机制土耳其毕尔肯大学研究人员推出的微型四足机器人集合了传统微型、软体机器人的优点，能够爬越身高2.44倍高的障碍物，未来或可应用于检查、救援等场景。此外，为了使SQuad能够应用于更多场景，研究人员还在继续更新设计，钻研能提升机器人步态和动作的技术及性能更好的新型聚合物。研究团队正在增加一个身体收缩机制，“（它能）使我们的机器人在通过比其横截面面积小的开口时，短暂地收缩身体，就像老鼠的行为那样。我们还在研究机器人的动力学模型，以便更好地理解微型机器人、软体机器人的运动。”

丽莎老师讲机器人之土耳其比尔肯大学巴掌大的新型微型机器人欢迎收听丽莎老师讲机器人，想要孩子参加机器人竞赛、创意编程、创客竞赛的辅导，找丽莎老师！欢迎添加微信号：153 5359 2068，或搜索钉钉群：31532843。近日，土耳其毕尔肯大学的研究人员发明了一款微型四足机器人——SQuad。与现有微型机器人不同的是，SQuad用软材料制成，行动更加灵活，可以攀越其身高2.44倍的障碍，也能绕开障碍物。未来，SQuad或能用于检查狭小空间、在废墟中搜救等。土耳其毕尔肯大学的研究人员研究微型机器人已有将近10年时间，微型机器人有许多优点，比如所需材料较少、成本低廉、能够进入狭窄空间等。但是，现有微型机器人的缺点也比较突出。“他们的主要缺点之一是缺乏运动能力，特别是在不平坦地形上。”微型机器人的高度有限，运动时无法攀爬或避开障碍物，因此很容易在运动过程中被卡住。相比于微型机器人，软体机器人的运动性能更好。大多数软体机器人都是用气动执行器制造的。研究人员介绍：“这些气动执行器可以和软材料实现非常好的集成效果，但是它们需要一个压缩气源，这往往会使机器人变得笨重、或不允许无绳运动。研究团队试图将两种机器人的优点加以结合，制作出综合性能更好的机器人。首先，选用聚二甲基硅氧烷（PDMS）等软材料来增加微型机器人的“身体顺应性（body compliance）”，使其运动能力变强。通过使我们的微型机器人变得柔软，它们能够利用自己的身体顺应性越过障碍，就像昆虫、老鼠等生物系统那样。同时，微型机器人搭载常规执行器来实现小型化和无绳移动。经过尝试，研究人员制成了微型四足机器人SQuad。该机器人有手掌大小，装配了集成直流电动机的柔性C型腿，可以自由旋转。研究人员通过一系列试验评估了SQuad的性能，并将其与一个刚性材料制成的机器人进行比较。结果显示，SQuad的运动性能更好。SQuad能够爬过比其身高还高1.44倍的障碍物，但刚性机器人只能爬过其身高0.88倍的障碍物。研究人员认为，这是因为两款机器人身体顺应性的差异。在未来，SQuad可以在陆地上完成各种简单的任务。由于具备高度灵活性、身体顺应性和增强的穿越障碍能力，SQuad可以爬过狭小的开口及在非结构化或不平坦的地形上运动。研究人也对SQuad的应用表现出信心，“他们认为，通过在机器人背上加一个小型摄像机，我们可以将这种机器人用于检查目的；通过集成一个摄像机和麦克风，就可以将其用于在倒塌的建筑物下寻找幸存者。”结语：设计还在更新，或增加身体收缩机制土耳其毕尔肯大学研究人员推出的微型四足机器人集合了传统微型、软体机器人的优点，能够爬越身高2.44倍高的障碍物，未来或可应用于检查、救援等场景。此外，为了使SQuad能够应用于更多场景，研究人员还在继续更新设计，钻研能提升机器人步态和动作的技术及性能更好的新型聚合物。研究团队正在增加一个身体收缩机制，“（它能）使我们的机器人在通过比其横截面面积小的开口时，短暂地收缩身体，就像老鼠的行为那样。我们还在研究机器人的动力学模型，以便更好地理解微型机器人、软体机器人的运动。”

Establishing Trust & Accountability Within A Remote WorkforceThis week, we are launching Toptal’s “Rise of Remote” series, a special edition of The Talent Economy Podcast, featuring advice and perspectives from experts in remote work. Prompted by the COVID-19 pandemic that has accelerated the gradual advance of remote work into a stampede, we thought it was extraordinarily relevant to create a special series dedicated to hearing from experts on how to succeed when working remotely. In this episode, I’m joined by Toptal’s VP of Product, Kleanthis Georgaris.Kleanthis drives the evolution of Toptal's platform and associated products, working closely with operations and engineering teams to drive and support our hypergrowth by providing a seamless, on-demand experience for clients and network talent. He specializes in digital talent networks, leveraging a diverse background at Microsoft, McKinsey, and many early- and late-stage startups, as well as launching a startup of his own.Kleanthis and I discuss remote work best practices and how to structure a product team in, and for, a remote environment. We deep dive into the importance of communication, transparency, work-life balance, and how to overcome the “trust barriers” that often stereotype remote work.Questions I ask:What has been your journey from working on location to now managing and leading a team in a fully remote, distributed environment?What advice would you give to other leaders, or first-time remote PdMs, on the frequency of team communication to ensure transparency?What are Toptal’s best practices for a product brainstorming or ideation exercise?How would you describe the impact of the current global crisis on remote work?In this episode, you will learn:Kleanthis’ advice to product leaders on staying connected in a remote environment.What sets Toptal apart.How to manage information overload in a remote setting by identifying information from noise.Kleanthis’ advice to managers and employees on how to be successful and stay connected when working remotely.Connect with Kleanthis:LinkedInEmail: kleanthis@toptal.com See acast.com/privacy for privacy and opt-out information.

In Folge 85 geht es mal wieder um Informationssysteme im Krankenhaus und wir schauen auf die Intensivstation. Dort sind Patientendatenmanagementsysteme (PDMS) unverzichtbare Helfer für das Monitoren von Vitaldaten. Welche Aufgabe diese Systeme darüber hinaus übernehmen, ob dafür eine Zertifizierung als Medizinprodukt notwendig ist und wie es sich so mit der Interoperabilität dieser Systeme verhält erläutert Bernhard zusammen mit seinem Gast Janko Ahlbrandt. In den News zuvor sprechen Christian und Renato über die Nutzenbewertung von Apps und synthetische Daten, ehe sie Richtung Metall-spielender KI abdriften. Und ein Intro gibt es diesmal auch wieder :-) Shownotes https://www.xing.com/profile/Janko_Ahlbrandt/cv https://www.aerztezeitung.de/politik_gesellschaft/psychotherapeutische_versorgung/article/993154/psychotherapeuten-mahnen-medizinische-apps-brauchen-nutzennachweis.html?sh=2&h=541880579 https://www.nature.com/articles/s41467-019-10933-3

欢迎收听丽莎老师讲机器人，想要孩子参加机器人竞赛、创意编程、创客竞赛的辅导，找丽莎老师！欢迎添加微信号：153 5359 2068，或搜索微信公众号：我最爱机器人。丽莎老师讲机器人之人造毛毛虫？多腿机器人。香港城市大学(CityU)的研究人员开发出了一种新型的微型软机器人。它的腿像毛毛虫一样，可以承受较大负载并能适应恶劣的环境。这种微型运输机器人可以为人体内药物运输技术铺平道路。让这个微型机器人脱颖而出的是它数百条不到1毫米的尖腿。而这种独特的设计并不是随意为之，研究小组研究了数百种地面动物的腿部结构，特别是腿长和腿间距的比例，研究对象包括那些有2条、4条、8条或更多腿的动物，从那里，他们得到了灵感。机器人的身体厚度约为0.15毫米，每条锥形腿长0.65毫米，两腿之间的距离约为0.6毫米，腿长与腿宽之比约为1:1。锥形的腿大大减少了机器人与物体表面的接触面积，从而减少了与表面的摩擦。实验室测试表明，这种多腿机器人在干、湿环境下的摩擦力比无腿机器人小40倍。除了多腿设计，材料也很重要。该机器人由嵌入了磁性颗粒的聚二甲基硅氧烷(PDMS)制成，因此通过施加电磁力就能远程控制机器人。通过磁力控制，机器人可以以襟翼推进模式或倒立摆模式移动，也就是说，它可以用前脚向前翻腾，也可以用左右脚交替站立来摆动身体。香港城市大学机械工程系(MNE)的教授说：“人体内不同组织的崎岖表面和变化的纹理使体内运输极具挑战性。我们的多腿机器人在各种地形中都表现出了令人印象深刻的性能，因此在身体内药物输送方面具有广阔的应用前景。”研究小组进一步证实，当机器人遇到比他的腿长十倍的障碍物时，机器人能够抬起身体的一端，形成90度的角度，然后很容易地穿过障碍物。该机器人还可以通过增加电磁频率来提高移动速度。此外，该机器人还显示了出色的负载能力。实验室测试表明，该机器人能够承载比自己重100倍的负载。这种机器人具有超强的携带能力、高效的移动能力和良好的穿越障碍的能力，因此非常适合在恶劣的环境下使用，例如穿越消化系统将药物送到指定地点。但是，在对动物和人类进行进一步的测试之前，研究团队正在从三个方面进一步发展和完善他们的研究，即找寻一种可降解的材料，研究新的机器人形状，并添加额外的功能。研究团队说希望在未来两到三年内制造出一种可生物降解的机器人，这样它就能在完成药物运送任务后自然分解。

KIS, RIS, PACS, DMS, PDMS, LIS.. Was wäre die Krankenhaus-IT nur ohne Abkürzungen? Und was wäre sie ohne einen Kommunikationsserver zwischen diesen ganzen Abkürzungen, der Sprachbarrieren überwindet und Kommunikation sicherstellt? In Podcast #43 erläutern Renato und Christian, warum in vielen Krankenhäusern heutzutage Kommunikationsserver stehen, was diese so alles können müssen, welche Vor- und Nachteile sich aus ihrem Einsatz ergeben und welche Anbieter es gibt. Als News gibt es in diesem Podcast den ersten Arzt, der an der Telematikinfrastruktur angeschlossen wurde, eine smarte Pille, die dem Arzt meldet, wenn sie im Magen angekommen ist, den Börsengang der Healthineers und ein Statement der Ethikkommission zum Thema Big-Data in der Medizin.   http://www.healthcaremarketing.eu/unternehmen/detail.php?rubric=Unternehmen&nr=52523&nr=52523#52523 http://www.ethikrat.org/presse/pressemitteilungen/2017/pressemitteilung-08-2017 http://e-health-com.de/details-unternehmensnews/cgm-bindet-erste-praxis-an-die-telematikinfrastruktur-an/3360afa121ed5e2575e2b51ca5b76a6f/ http://podplayer.net/#/?id=43496939 https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584933.htm

This video is a tutorial on performing O2 plasma treatment of PDMS using a microwave oven. The demonstration includes how to set up the treatment, as well as testing the hydrophobicity of the treated PDMS.

This video is a tutorial of how to prepare nickel-doped PDMS. A series of tests of the thermal, electrical, and magnetic properties of different concentrations of doping are shown.

This video is a demonstration of three tests on microfluidic devices on the MIT logo and a fluid flow visualization.

This video is a tutorial of preparing a test pattern through a process of curing the PDMS, opening the microfluidic inlet and outlet ports, cleaning the PDMS, bonding it to glass, and using corona treatment.

Oxygenic photosynthesis converts light energy into chemical energy and is responsible for generating most of our atmosphere’s oxygen and biomass on earth. Several multimeric protein complexes are involved in the underlying photosynthetic electron transfer chain with photosystem II (PSII) representing the initial complex mediating the extraction of electrons from water molecules, thus generating molecular oxygen as a by-product. During recent years, the structural details and components of the PSII complex, including its inorganic and organic cofactors, have been elucidated in great detail. However, little is known about the assembly pathway of this at least 20 protein subunits containing machinery. Previous work indicated that PSII assembly occurs in a step-wise fashion and requires a number of facilitating factors, which interact transiently with nascent PSII complexes. Earlier studies of one of those assembly factors, the cyanobacterial PratA protein, suggested that PSII biogenesis does not only underlie a temporal order but is also organized at the spatial level, as PratA was shown to mark a special intermediate membrane subfraction (PDMs), hypothesized to represent regions for initial steps of PSII biogenesis. The presented work focused on a more detailed characterization of PDMs, clearly supporting their significance not only with regard to early protein assembly, but also concerning pigment synthesis and integration into the PSII precomplexes. The PDMs could further be allocated to special membrane regions, named biogenesis centers, at sites where thylakoid membranes converge to the plasma membrane, thus demonstrating the spatial organization of PSII assembly at the cellular level. Moreover, a novel function of PratA in preloading of PSII with Mn2+ ions, necessary for construction of the water-splitting complex, was discovered. Concomitantly with progression of the assembly, the nascent PSII complexes are transported from the PDMs to the thylakoid membrane system, where Sll0933 – a novel PSII assembly factor identified in this thesis – mediates the integration of the PSII inner antenna proteins followed by completion of the assembly process. Additionally, it could be shown that many of the so far identified facilitating factors interact with each other and, thus, form a complex network for PSII assembly. Especially the interaction between the two assembly factors YCF48 and Sll0933 was characterized in more detail, revealing a successive mode of action with YCF48 operating upstream of Sll0933. Taken together, the presented results enable the development of an extended and elaborated model of PSII assembly, which is a concerted process connecting protein and cofactor synthesis/integration in a spatiotemporal manner, and thus contribute to a more profound understanding of photosynthesis itself.

The article by Rajendrani Mukhopadhyay explores the pros and cons of PDMS as a material for microfluidic devices.